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ABSTRACT: The replacement of one chemical motif with another that is broadly similar
is a common method in medicinal chemistry to modulate the physical and biological
properties of a molecule (i.e., bioisosterism). In recent years, bioisosteres such as cubane
and bicyclo[1.1.1]pentane (BCP) have been used as highly effective phenyl mimics. Herein,
we show the successful incorporation of a range of phenyl bioisosteres during the open-
source optimization of an antimalarial series. Cubane (19) and closo-carborane (23)
analogues exhibited improved in vitro potency against Plasmodium falciparum compared to
the parent phenyl compound; however, these changes resulted in a reduction in metabolic
stability; unusually, enzyme-mediated oxidation was found to take place on the cubane core.
A BCP analogue (22) was found to be equipotent to its parent phenyl compound and
showed significantly improved metabolic properties. While these results demonstrate the
utility of these atypical bioisosteres when used in a medicinal chemistry program, the search
to find a suitable bioisostere may well require the preparation of many candidates, in our
case, 32 compounds.
■ INTRODUCTION
Phenyl rings are ubiquitous in medicinal chemistry, appearing in
all manners of biologically relevant molecules. Yet phenyl groups
may not always be the optimal motif: they are relatively non-
polar; theymay be involved in π−π stacking interactions that can
contribute to low aqueous solubility or have limited
bioavailability; and they can be a metabolic liability.1,2
Fortunately, there are several well-established strategies for
addressing solubility issues.3,4 Perhaps the most common
strategy is to append charged or polar groups such as alcohol
or amine moieties to the parent compound. Such modifications
will typically reduce the hydrophobicity of the compound, but
can often dramatically worsen potency. Similar effects may be
seen through the use of heterocyclic ring replacements, but again
these may alter the potency of the desired compound.5
Alternatively, modifications can be made to alter the crystal
packing of a compound by either removing aromaticity via
removing the phenyl rings or changing the molecular geometry
or topology. For example, replacement of a phenyl ring by an
alkyl group (linear, cyclic, or caged) may help improve solubility
by eliminating π−π stacking interactions and have the added
advantage of introducing further options for chemical
derivatization that may not be accessible with a phenyl ring.
Again, however, there is the caveat that these changes can heavily
influence the binding interactions between a drug and its
ultimate biological target.
Our recent experiences in dealing with such issues are related
to an antimalarial medicinal chemistry program. Malaria is one
of the most prevalent infectious diseases affecting low-income
countries, with 219 million cases reported worldwide in 2017, 2
million more cases than the previous year. This translates to
around 1200 deaths per day, mostly involving children.6 With an
increasing number of reports of resistance to current treatment
and prevention strategies, new medicines must be discovered to
combat the disease.7,8 To help address this, the Open Source
Malaria (OSM) consortium was created, with the aim of
discovering new antimalarial medicines using an inclusive
community operating on open-science principles, where all
data and experiments are shared in real time (for example, every
experiment involved in the current study is freely available to
view online).9 The most recent, fourth series examined by the
consortium, the so-called Series 4 triazolopyrazine antimalarials,
originated from a high-throughput screen performed at Pfizer in
collaboration with the Medicines for Malaria Venture (MMV).
The series was then passed to TCG Lifesciences for further
optimization before being donated to the OSM consortium in
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2013.10 The series has produced many compounds with potent
(<100 nM) activity against Plasmodium falciparum, promising
physicochemical properties, and low toxicity (Figure 1). Two
compounds from the series were shown to have high potency in
an in vivomouse model (full results to be reported elsewhere).11
While the potency of compounds in the series has been
frequently high, issues still remain, particularly with regard to
poor solubility and moderate clearance rates. As such,
modification of the phenyl groups present in the structure was
seen as an attractive strategy for mitigating these issues. Careful
consideration of such modifications was required as the series is
in the lead optimization stage of development and displays high
sensitivity to functional group changes.
The approach adopted was based on isosteres, a concept first
described by Harris Friedman in 1950 as “compounds or groups
that possess near-equal molecular shapes and volumes,
approximately the same distribution of electrons, and which
exhibit similar physical properties”.12 The use of a bioisostere
(isosteres that have the same type of biological activity) can be
an extremely useful strategy in medicinal chemistry programs for
altering the physical and biological properties of a compound.13
Classical bioisosteres focus on the use of structurally simple
atoms, groups, and ring equivalents (e.g., replacement of a
phenyl ring with a pyridine ring), while nonclassical bioisosteres
may differ quite dramatically from the original group.14−17
One of themore interesting nonclassical phenyl bioisosteres is
cubane, a motif that has been used in medicinal chemistry
projects spanning a range of applications.18−20 The size and
shape of cubane mimic the rotational volume and shape of a
phenyl ring.21 Several biologically active molecules have been
evaluated for their ability to tolerate a cubane as a replacement
for an aromatic ring, examining changes in biological activity,
solubility, metabolism, stability, and synthetic tractability
(Figure 2A).21 The five compounds evaluated included those
with chemotherapeutic (Vorinostat), anesthetic (Benzocaine),
and neotropic (Leteprinim) applications. It was found that four
of the five showed equivalent or improved potency when the
phenyl ring was replaced with a cubane. In these four cases, the
slight increase in log P values with the cubane replacements
(largest difference of log P ∼ 0.5) did not have a significant
impact on compound solubility. However, in the one case that
led to decreased potency, a much larger increase in log P (∼1.4)
was seen for the cubane analogues that translated to a large
reduction in solubility. A more recent evaluation of a further five
pharmaceuticals revealed a mixed effect of the cubane
replacement on both potency and solubility.22
In a similar manner to cubane, the bicyclo[1.1.1]pentane
(BCP) motif has recently found use as a nonclassical phenyl ring
bioisostere.23 While the size of the BCP motif does not match
that of benzene as closely as cubane (vide inf ra), its use as an
effective phenyl bioisostere has been demonstrated in a number
of cases. For example, the phenyl ring in a γ-secretase inhibitor
currently in development was replaced with the BCP motif
resulting in a compound with not only equipotent enzyme
inhibition but also improved passive permeability, aqueous
solubility, and oral absorption characteristics.24 In another
example, a BCP replacement in a LpPLA2 inhibitor resulted in
maintenance of potency while improving the compound’s
physicochemical properties (B, Figure 2).25 Increasing work has
Figure 1. Series 4 triazolopyrazines possess promising biological
properties; however, further improvements to solubility and metabolic
stability are required.
Figure 2. Examples of the use of phenyl bioisosteres. (A) Cubane in the insecticide diflubenzuron. (B) Bicyclo[1.1.1]pentane (BCP) in the LpPLA2
inhibitor darapladib. (C) closo-1,2-Carborane in the antiestrogen agent tamoxifen.
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been done in recent years with the synthesis of BCP building
blocks allowing for more possibilities for its use as a phenyl
bioisostere.26,27
Perhaps less immediately obvious to medicinal chemists is the
use of the boron-rich icosahedral clusters known as carboranes
and their potential application as phenyl and adamantyl
bioisosteres.28 One prominent example is the closo-carboranyl
derivative (closed form with all carbon and boron vertices) of
tamoxifen.29 The resulting carboranyl compounds showed high
activity as antiestrogen agents and were even found to be more
stable to degradation than tamoxifen (C, Figure 2). Another
example is that of asborin, a closo-1,2-carborane derivative of
aspirin.30 Interestingly in this case, the pharmacological profile
of the resulting carboranyl derivative was changed drastically.
Instead of acting as a selective cyclooxygenase enzyme inhibitor
(like aspirin), asborin was instead found to be a potent inhibitor
to the unrelated aldo/keto 1A1 reductase family.31 Other
examples of carboranyl bioisosteres of polycycles such as
adamantanes can be found in medicinal chemistry, including
their in vivo application as central nervous system (CNS)-
modifying agents.32
While it is not unusual for a medicinal chemistry campaign to
explore select phenyl bioisosteres (typically cubane and
BCP),33,34 it is much less common to see the wider range of
possible bioisosteres used in a single lead optimization program.
In the case of the OSM Series 4 triazolopyrazines, the changes
required to achieve our goal (improve the aqueous solubility and
metabolic clearance parameters, but not significantly change the
potency) were not immediately clear, in part because the project
was a phenotypic drug-discovery program with no confirmed
biological target. While the calculation of cLog P values may give
an indication of the potential aqueous solubility of a compound,
these values can only be used as a general guideline and do not
necessarily provide a good indication of bioavailability (note
that in this study, cLog P was prioritized over other possibly
relevant parameters, such as molecular weight or total polar
surface area; these values may be found in the Supporting
Information (SI), though they appear to show no correlation
with experimental potency). This is particularly notable for
some of the phenyl bioisosteres that are mentioned above, where
the calculated log P values can be inconsistent across different
software platforms,35 particularly where the carborane motif is
involved; in such cases, it may be necessary to measure solubility
experimentally.22 Accordingly, we investigated a wide range of
possible phenyl bioisosteres for Series 4, without relying heavily
on the calculated cLog P values as a guide.
■ RESULTS AND DISCUSSION
Chemistry. The synthesis of the triazolopyrazine core was
achieved in three steps from the commercially available 2,6-
dichloropyrazine (Scheme 1). Initial displacement of a chlorine
atom with hydrazine hydrate gave 2-chloro-6-hydrazinylpyr-
azine (1). Condensation with the appropriate aldehyde afforded
the hydrazone intermediate (2a−g), which was subsequently
Scheme 1. Preparation of Series 4 Target Compoundsa
aSynthetic route to target compounds and subsequent derivatization where applicable. Reaction conditions: (i) N2H4·H2O, EtOH, 80 °C,
overnight; (ii) aldehyde, EtOH, room temperature (rt), overnight; (iii) PhI(OAc)2, CH2Cl2, rt, overnight; (iv) alcohol, 18-crown-6, PhMe, rt,
overnight; (v) TFA, CH2Cl2, rt, overnight; (vi) see the SI; (vii) CsF, EtOH, 80 °C, 25 h. (B) Aldehyde and alcohol building blocks were either
commercially available or synthesized; sat. het. = saturated heterocycle; hyd. cage = hydrocarbon cage; carb. isom. = closo-carborane isomer. (C)
Target compounds.
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cyclized to give the chlorinated triazolopyrazine core (3a−g).
Final nucleophilic displacement of the chlorine atom with the
appropriate alcohol produced the desired target compounds 4−
31. A number of additional transformations were performed on
select target compounds. Deprotection of N-Boc compounds
14, 26, and 28was carried out using standard trifluoroacetic acid
(TFA) conditions to give the corresponding free amine
compounds 32, 33, and 34, respectively. Compounds 16 and
19were used to generate late-stage biofunctionalized derivatives
using dog or rabbit liver microsomes (see the Experimental
Section). In the case of the norbornene compound 16, oxidation
of the norbornene double bond led to a mixture of epoxides and
E and/or Z diol compounds (35 and 36). In the case of the
cubane compound 19, two metabolites were isolated and were
found to be hydroxylated on the cubane framework (37 and 38).
The reaction of compound 23 with CsF in EtOH gave the
hydrophilic nido-7,8-carboranyl derivative as its cesium salt 39.
In Vitro Activity. All compounds were evaluated for in vitro
antiplasmodial activity against the 3D7 strain of P. falciparum.
The activities, indicated by their IC50 values, are summarized in
the SI and shown graphically in Figure 3. While the inherited
dataset for OSM Series 4 suggested an ether chain length of two
methylene groups between the heterocyclic core and the
northwest pendant phenyl ring was optimal, the specific
compounds to prove this relationship were absent from the
dataset. In order to validate this hypothesis, a set of compounds
with an ether methylene chain length from zero to three was
evaluated, clearly showing that this separation of the phenyl
from the core was indeed important to maintain potency.
Specifically, any chain length other than two carbon atoms (6)
resulted in reduced potency with complete inactivity seen with a
phenol side chain (4).
Surprisingly, when the saturated heterocyclic derivatives (9−
14, 26−29, and 32−34) were evaluated, it was found that they
were all inactive with complete loss in potency compared to the
parent phenyl compound. This was seen in both the northwest
and northeast cases. The increased flexibility of these saturated
heterocycles is presumably contributing to this loss of activity.
Encouragingly, the comparable two- and three-methylene
linker cubane analogues 19 and 20, respectively, were only
slightly less potent than the phenyl compounds but also followed
the trend of decreased potency with longer chain length. The
recovery of activity compared to the saturated heterocyclic
derivatives provides strong evidence of the ability of cubane to
mimic the rotational volume of a phenyl ring. It was also verified
that the mechanism of action had not changed following these
modifications: the potent bioisosteric compounds showed
activity in an ion regulation assay, which is linked to the
malarial target PfATP4.36,37
However, on the contrary, the northeast cubane derivative 31
was found to be completely inactive, whereas the analogous
phenyl compound 30 remained potent. This surprising result
suggests that the ability of cubane to mimic a phenyl ring is
reduced if the phenyl ring possesses restricted rotation (as is
assumed to be the case here), in which case the volume occupied
by the phenyl ring is not well mimicked by the bulk of the
Figure 3.Heat map of in vitro potency. Color gradient: green = <1 μM; orange = 1−2.5 μM; red = >2.5 μM. (A) Variations in potency with northwest
phenyl replacements. (B) Late-stage biofunctionalization compounds evaluated at lower concentrations than the other compounds. (C) Variations in
potency with northeast phenyl replacements.
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cubane. Alternatively, the change may have removed a key π-
stacking interaction. Considering that all northeast phenyl
replacements resulted in completely inactive compounds, the
remaining investigation was focused on the further exploration
of the northwest pendant phenyl ring.
The BCP derivative 22 was relatively well tolerated compared
to the analogous benzylic ether compound 3 with only a slight
decrease in activity. This loss in potency may be due to the
smaller size of the BCP motif; however, it is noted that many
examples of the use of BCP as a phenyl bioisostere tend to result
in more significant changes to the metabolic and pharmacoki-
netic properties instead, as will be discussed below.
The larger adamantyl derivatives were less well tolerated with
the one- and two-carbon chain compounds (17 and 18,
respectively) showing potencies approximately 2−9 times
lower than the corresponding phenyl compounds (5 and 6,
respectively). This result may be attributed to the larger volume
of adamantane (vide inf ra) compared to either a cubane or a
rotating phenyl ring.38 Other hydrocarbon-caged derivatives
including nopol, norbornene, and trishomocubane (15, 16, and
21, respectively) were better tolerated; however, these were still
found to be less potent than the parent phenyl compounds.
As a final investigation point, the closo-1,2-, 1,7-, and 1,12-
carborane isomers were installed in place of the northwest
phenyl position. Unexpectedly, the closo-1,2- and 1,7-carborane
isomers (23 and 24, respectively) showed potencies greater than
not only all of the other previous derivatives but also, more
importantly, the parent phenyl compound. A significant drop in
activity was seen between the closo-1,7- and 1,12-carborane
isomers (24 and 25). The potency was observed to decrease
from closo-1,2- < 1,7- < 1,12-carborane. This trend is likely
related to the differences in polarity (and hydrophobicity) of the
three carborane isomers.39 Themore hydrophobic and less polar
the closo-carborane isomer is (as pertaining to the relative
positions of the two carbon atoms in each carborane cage and
the resulting dipole moments), the less potent the final
compound was found to be.
In a similar manner to closo-1,2-carborane, the hydrophilic
nido-7,8-carborane cage (open form with one boron vertex
removed) has also shown potential as a phenyl bioisostere both
in a carborane variant of tamoxifen40 and trimethoprim,41 for
example. In the latter case, the nido form was found to be less
toxic than the closo form; however, it also performed less usefully
as a boron neutron capture therapy (BNCT) agent, with poorer
tumor retention and lower selectivity ratios for boron
distribution in tumor versus normal tissues. In our case, the
nido-7,8-carborane 39 was also found to be less active, with its
potency decreasing significantly compared to the closo-1,2-
carborane 23. Selective removal of a single BH group from the 3
(or 6) position of the closo-carborane cage affords a hydrophilic,
anionic species, which would likely show diminished binding to
a hydrophobic receptor pocket.
With these encouraging results, select compounds were
further evaluated for a number of other properties including
toxicity, solubility, and metabolic stability.
Toxicity. Having synthesized a number of highly potent
compounds that possessed unusual motifs, it was important to
check for any associated toxicity. While a number of examples in
the literature show no significant increases in toxicity with
cubane bioisosteres,42,43 carborane-associated toxicity has been
far less studied. Encouragingly, when closo- and nido-carborane
compounds 23 and 39 were evaluated for potential cytotoxicity
in HepG2 cells, both compounds were found to be inactive, with
IC50 values of >10 μM. Compounds 6, 19, and 23 were
additionally evaluated for their human ether-a-̀go-go-related
gene (hERG) activities with the phenyl compound 6 showing
moderate activity (IC50 = 7.41 μM) and the cubane and
carborane analogues showing slightly greater potencies (IC50 =
4.26 and 3.62 μM, respectively). While these values are not
entirely desirable, further hERG optimization to lower
inhibition may be achieved through further derivatization.
Metabolic and Physicochemical Properties. The
reported effects on the metabolic and physicochemical proper-
ties of phenyl bioisosteric replacement by cubane have been
mixed. While a number of cases have reported improvements in
solubility following cubane substitutions,34 the trend for
metabolic stability is less consistent. There have been reports
of both increased21 and decreased33 metabolic stability as a
result of cubane substitution. In the present case, when
compounds 6, 19, and 23 were evaluated for their metabolic
and physicochemical properties, they were found to perform
poorly compared to the parent phenyl compound (Table 1).
The solubility at pH 6.5 was low for 19 and 23 (<1.6 μg/mL)
compared to 6 (6.3−12.5 μg/mL). Both 19 and 23 also
exhibited high clearance and short half-lives in human liver
microsomes (HLM) and mouse liver microsomes (MLM). In
rat cryopreserved hepatocytes (RCH), 19 and 23 showed
intermediate and low degradation rates with low clearance rates
and short half-lives. It is likely that clearance of the parent
compound occurs via benzylic oxidation44 and that the removal
of this phenyl ring should slow down the rate of clearance due to
the absence of the benzylic position. Our results suggest that the
Table 1. Metabolic and Physicochemical Properties of Select Series 4 Phenyl Bioisosteres Compoundsc
acLog P values calculated using DataWarrior. bCarboranes are not currently handled well by prediction software: when this value is calculated with
ChemDraw Professional, the value is 4.0. cThe color coding of the values indicates the performance of the compound (green being more desirable).
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incorporation of cubane in place of phenyl has led to the cubane
becoming a metabolic liability. This appears to be in contrast to
the notion that cubane derivatives are more metabolically stable
to hydroxylation than the corresponding phenyl analogues
(increased s-character from the strong and hindered tertiary C−
H bonds).45 In our case (vide inf ra), it appears that the
metabolic “hotspot” has shifted onto the cubane itself.
Encouragingly, the BCP derivative 22 was found to possess
significantly improved metabolic and physicochemical proper-
ties compared to the parent phenyl compound. While the
solubilities were within the same range, 22 exhibited lower
clearance and shorter half-life values across human, mouse, and
rat liver microsomes.
Late-Stage Biofunctionalization. Further light is shed on
these results by the isolation of the four metabolites (35−38),
which were found to be inactive. A similar metabolism of phenyl-
substituted compounds leads to oxidation at the benzylic
position, as expected (these will be reported separately for this
series), whereas for cubane, the hydroxylation occurred on the
hydrocarbon cage instead, i.e., we observe preferential
hydroxylation of the benzylic position in the phenyl case but
core hydroxylation for cubane. This is unexpected. Experiments
on enzymatic oxidation of methylcubane have indicated that
hydroxylation on themethyl group is favored over hydroxylation
on the cubane framework with only small amounts of the latter
products being identified.46,47 If the cubane does become
hydroxylated, it is thought that such products are unstable and
lead to rearrangement to a ring-opened ketene product.48 This
possibly explains why there are a small number of reports of
hydroxycubanes in the literature.49,50 The present isolation of
hydroxycubane derivatives is therefore unusual.
Comparison of Phenyl Bioisosteres. In literature reports
where phenyl bioisosteres have been used, a size comparison
between the bioisostere and the phenyl ring is often given. There
is some variation between these values. For example, in one
report, the diagonal C−C atom distances for benzene and
cubane have been quoted as the same (2.70 Å),51 while another
report has quoted them as different (2.82 and 2.72 Å for benzene
and cubane, respectively).34 Similar disagreements have been
seen for BCP comparisons as well (vide inf ra). For meaningful
comparisons, a unified approach was preferable. We have
therefore examined deposited crystal structure files from The
Cambridge Crystallographic Data Centre (CCDC) and
calculated the dimensions of key phenyl bioisosteres with
UCSF Chimera, allowing for a direct comparison (Table 2).
While the literature atom distances are, for the most part,
consistent with those calculated with UCSF Chimera, there is a
notable increase of about 10−15% between the calculated and
literature values for surface area and volume. It remains largely
unclear as to which methods provide calculated values closest to
those measured from X-ray structures; accurate calculations
would be useful for calculating the dimensions of novel
bioisostere motifs. Most literature sources only provide a small
selection of calculations, and specifically for volume calculations,
none take into account the free rotation of the bioisostere.
However, as these comparisons are often made to show the
relative dimensions, calculations performed using the same
method or program would be the most reliable, such as in this
case with UCSF Chimera. Nevertheless, it is interesting to note
how different the dimensions can be for phenyl and an effective
bioisostere. For example, the closo-carborane core was found
experimentally to be an excellent mimic, yet its volume is
significantly larger than that of a phenyl ring, meaning the
functional significance of bioisosteric size comparisons must be
treated with care.
■ CONCLUSIONS
While phenyl rings can be found in all manners of biologically
important molecules, they may not always be the ideal motif for
druglike molecules. Using classical and nonclassical bioisostere
replacements, the biological properties of a compound may be
altered in dramatic ways. These changes may not always result in
the desired improvements, and accurate predictions can be
challenging. In phenotypic projects like this one, which are now
so common in early-stage drug discovery, rational modifications,
such as the substitution of a rotatable phenyl group with a
cubane, may or may not lead to improvement in the overall
properties of the molecule given how many other potential
interactions may be involved before the molecule reaches its
intended target. As seen in this work, equivalent substitutions for
different phenyl rings in the same molecule can lead to widely
different potencies. In any given case, it may well be necessary to
Table 2. Structural Information of Select Phenyl Bioisosteres Calculated Using UCSF Chimeraf
structure (CCDC Identifier) C−C distance (Å) H−H distance (Å) surface area (Å2)a volume (Å3)a
Benzene (ABELUO) 2.77 (2.70;51 2.79;21 2.8234) 4.63 (5.9052) 89.7 70.1 (79.038)
Cubane (CUBANE) 2.68 (2.70;51 2.7221,34) 4.70 (4.8853) 103 87.1
Adamantane (ADAMAN08) 3.53 4.92 (6.36;54 6.4052) 126 (13452) 119 (128;52 13638)
BCPb (HEHRUJ) 1.88 (1.70;24 1.85;34 1.9051) 4.78c 80.2d 61.4d
Norbornene (HOBBOP) 2.89 4.64 101 84.8
closo-1,2- Carborane (TOKGIJ) 3.23e 5.26 135 127 (14838)
closo-1,7- Carborane (TOKGOP) 3.20e 5.12 134 126 (14338)
closo-1,12- Carborane (TOKGUV) 3.06 4.85 (5.3555) 136 127 (14138)
aSurface areas and volumes were calculated using a model of the solvent-excluded molecular surface with hydrogen atoms included. bR = terminal
alkyne. cAlkyne C−C distance. dSurface area and volume calculated without alkyne substituents. eCarborane C−B distance. fWhere they exist,
literature values are shown in parentheses. C−C and H−H distances are indicated in purple and orange, respectively.
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explore a considerable range of possible bioisosteres before
arriving at an effective solution. In our case, we have identified a
series of novel closo-carborane containing compounds that
possessed potencies greater than that of the parent phenyl
compound. To get to this point required the synthesis of 30
variations of the initial hit. More rational substitutions may be
possible in cases where the structures of the biological targets are
known, particularly through consideration of the volumes
occupied by the various isosteres.
■ EXPERIMENTAL SECTION
General Information. Reagents were purchased from Sigma-
Aldrich, Alfa Aesar, Acros Organics, Merck, Fischer Scientific, Matrix
Scientific, Ajax, or Fluorochem. Unless otherwise specified, the reagents
were used without further purification. Anhydrous conditions:
glassware was dried at >130 °C for >12 h, assembled hot, and allowed
to cool under a high vacuumwhere appropriate or purged with inert gas.
Anhydrous solvents were obtained from the PureSolv system or by
drying over activated 3 Å molecular sieves. Nitrogen gas was dried over
silica and calcium chloride. Argon gas was used as acquired. The phrase
in vacuo corresponds to ∼1 mbar on a Schlenk line. Reduced pressure
means under rotary evaporation at 40 °C from 900 to 50 mbar. Flash
chromatography was performed on Davisil Grace Davison 40−63 μm
(230−400 mesh) silica gel or on a Biotage Isolera One. Analytical thin-
layer chromatography was performed on Merck Silica Gel 60 F254-
precoated aluminum plates (0.2 mm) and visualized with UV
irradiation (254 nm) and potassium permanganate, anisaldehyde or
ninhydrin staining. High-temperature reactions were carried out in
silicone oil baths, controlled by temperature probe in the oil bath.
Melting points (mp) were recorded on a Stanford Research Systems
OptiMelt at 1 °Cmin−1 (capillaries ø = 1.5−1.6mm, 90mm) or a Stuart
SMP10 at 2 °C min−1 (capillaries ø = 1.8−1.9 mm, 100 mm). Infrared
spectroscopy was carried out on a Bruker α-E (attenuated total
reflectance) without atmospheric compensation and processed using
OPUS 7.0 software. Samples were analyzed neat. Nuclear magnetic
resonance spectroscopy was carried out at 300 K on Bruker
spectrometers: AVANCE 200 (1H at 200 MHz), AVANCE 300 (1H
at 300MHz, 13C at 75MHz), AVANCE III 400 (1H at 400MHz, 13C at
101 MHz), or AVANCE III 500 (1H at 500 MHz, 13C at 126 MHz).
Spectra were processed using Bruker Topspin or Mestrelab Research
Mnova. Deuterated solvents (CDCl3, DMSO-d6, CD3OD, acetone-d6)
were obtained from Cambridge Isotope Laboratories. 1H and 13C
chemical shifts are reported in parts per million (ppm) with respect to
tetramethylsilane (TMS) at 0.00 ppm. The chemical shifts of the
spectra were calibrated to residual solvent peaks (1H: CHCl3 7.26 ppm,
dimethyl sulfoxide (DMSO) 2.50 ppm, MeOH 3.31 ppm, (CH3)2CO
2.05 ppm, TMS 0.00 ppm; 13C: CHCl3 77.16 ppm, DMSO 39.52 ppm,
MeOH 49.00 ppm, (CH3)2CO 39.52 ppm, TMS 0.00 ppm).
1H signal
multiplicity is reported as: singlet (s), doublet (d), triplet (t), quartet
(q), pentet (p), and combinations thereof, or multiplet (m). Broad
signals are designated broad (br). Coupling constants (J) are reported
in hertz (Hz). Integrals are relative. app = apparent when the
multiplicity was unexpected, e.g., coincidental or unresolved. Low-
resolution mass spectrometry (m/z) was carried out on a Finnigan
quadrupole ion-trap mass spectrometer using electrospray ionization
(ESI) or atmospheric-pressure chemical ionization (APCI). High-
resolution mass spectrometry (HRMS) was performed on a Bruker 7T
FT-ICR using ESI or APCI. Positive and negative detection is indicated
by the charge of the ion, e.g., [M +H]+ indicates positive-ion detection.
Purity of all compounds was >95% as determined by NMR
spectroscopy (provided for all compounds evaluated biologically).
2-Chloro-6-hydrazinylpyrazine (1). To a solution of 2,6-dichlor-
opyrazine (22.3 g, 150 mmol, 1 equiv) in EtOH (428 mL, 0.35 M) was
added hydrazine monohydrate (14.7 mL, 299 mmol, 2 equiv). The
reaction was heated to 80 °C until completion, as indicated by thin-
layer chromatography (TLC). The solution was allowed to cool to rt,
and the solvent was removed under reduced pressure. H2O and EtOAc
were added, and the organic layer was separated. The aqueous layer was
extracted with EtOAc (3×), and the combined organic layers were
washed with brine, dried (Na2SO4), filtered and concentrated under
reduced pressure to give 1 as fine yellow needles (19.7 g, 93%); Rf 0.12
(30% EtOAc in hexanes); mp 133−135 °C (lit.56 136−139 °C); 1H
NMR (300 MHz; CDCl3) δ: 8.13 (s, 1H), 7.89 (s, 1H), 6.38 (s, 1H),
3.86 (s, 2H); 13CNMR (75MHz; CDCl3) δ: 156.4, 146.7, 132.4, 129.0.
Spectroscopic data matched those in the literature.56
General Procedure for the Synthesis of 2a−g.Compound 1 (1
equiv) was stirred into EtOH (112 mM). Aldehyde (1 equiv) was
added, and the reaction was stirred at rt until completion, as indicated
by TLC. The solvent was removed under reduced pressure to give
compounds 2a−g, which were carried forward without further
purification unless otherwise stated.
(E)-2-Chloro-6-(2-(4-(difluoromethoxy)benzylidene)hydrazinyl)-
pyrazine (2a). From 4-(difluoromethoxy)benzaldehyde (1.92 mL, 14.5
mmol) and 1 (2.10 g, 14.5 mmol) to give 2a as light brown crystals
(3.29 g, 76%); (3.29 g, 76%); Rf 0.63 (25% EtOAc in hexanes); mp
197−200 °C; 1H NMR (300 MHz, DMSO-d6) δ: 11.55 (s, 1H), 8.56
(s, 1H), 8.05 (d, J = 5.2 Hz, 2H), 7.79 (d, J = 8.5 Hz, 2H), 7.29 (t, J =
73.9 Hz, 1H), 7.22 (d, J = 8.4 Hz, 2H); 13CNMR (75MHz, DMSO-d6)
δ: 152.3, 151.7, 145.6, 141.6, 132.4, 131.5, 128.8, 128.3, 118.8, 116.2 (t,
J = 257.9 Hz).
tert-Butyl (E)-3-((2-(6-Chloropyrazin-2-yl)hydrazinylidene)-
methyl)pyrrolidine-1-carboxylate (2b). From 1-boc-3-pyrrolidine-
carbaldehyde (200 mg, 1.00 mmol) and 1 (145 mg, 1.00 mmol);
purified by automated flash chromatography on silica (Biotage Isolera,
6−50% EtOAc in hexanes) to give 2b as an off-white powder (215 mg,
66%); Rf 0.27 (25% EtOAc in hexanes); mp 124−128 °C; 1H NMR
(400MHz, CDCl3) δ: 8.47 (s, 1H), 8.45 (s, 1H), 7.98 (s, 1H), 7.16 (d, J
= 4.3 Hz, 1H), 3.61 (dt, J = 20.6 & 9.8 Hz, 1H), 3.54−3.44 (m, 1H),
3.44−3.32 (m, 2H), 3.09 (s, 1H), 2.18−2.06 (m, 1H), 2.06−1.90 (m,
1H), 1.46 (s, 9H); 13CNMR (101MHz, CDCl3) δ: 154.6, 152.0, 146.2,
144.9, 134.0, 129.1, 79.6, 48.9, 45.2, 41.4, 40.5, 28.6; m/z (ESI+) 348




pyrazine (2c). From tetrahydrofuran-3-carbaldehyde (50% in H2O,
800mg, 1.88mmol) and 1 (578mg, 1.88mmol); purified by automated
flash chromatography on silica (Biotage Isolera, 6−50% EtOAc in
hexanes) to give 2c as an off-white powder (662mg, 73%);Rf 0.28 (25%
EtOAc in hexanes); mp 135−138 °C; 1H NMR (400 MHz, CDCl3) δ:
8.46 (s, 1H), 8.40 (s, 1H), 7.98 (s, 1H), 7.14 (d, J = 5.9 Hz, 1H), 3.95
(ddd, J = 13.8, 8.4 & 6.6 Hz, 2H), 3.89−3.71 (m, 2H), 3.17 (dq, J = 13.8
& 6.3 Hz, 1H), 2.20 (dtd, J = 12.8, 7.8 & 5.4 Hz, 1H), 2.10−1.95 (m,
1H); 13CNMR (101MHz, CDCl3) δ: 152.0, 146.2, 146.0, 134.0, 129.1,
70.9, 68.2, 42.0, 30.6; m/z (ESI+) 249 ([M + Na]+, 100%); HRMS




methyl)piperidine-1-carboxylate (2d). From 1-boc-4-piperidine-
carboxaldehyde (400 mg, 1.88 mmol) and 1 (271 mg, 1.88 mmol);
filtered and washed with EtOH to give 2d as a light brown powder (352
mg, 55%); Rf 0.52 (25% EtOAc in hexanes); mp 179−183 °C; 1HNMR
(400 MHz, CDCl3) δ: 8.47 (s, 1H), 8.15 (s, 1H), 7.99 (s, 1H), 7.09 (s,
1H), 4.06 (br s, 1H), 3.85 (br s, 1H), 2.93 (q, J = 12.2 Hz, 2H), 2.47
(dq, J = 9.3 & 4.5 Hz, 1H), 1.99 (dd, J = 9.2 & 3.8 Hz, 1H), 1.74 (dd, J =
8.6 & 3.9 Hz, 1H), 1.66−1.44 (m, 2H), 1.46 (s, 9H); 13C NMR (101
MHz, CDCl3) δ: 154.9, 152.1, 146.2, 145.1, 134.0, 129.2, 79.9, 38.7,
28.6, 28.5, 24.4; m/z (ESI+) 362 ([M + Na]+, 100%); HRMS (ESI+)
found 362.1350 ([M + Na]+), C15H22ClN5O2Na
+ requires 362.1354.
(E)-2-Chloro-6-(2-((tetrahydro-2H-pyran-4-yl)methylene)-
hydrazinyl)pyrazine (2e). From 4-formyltetrahydropyran (200 mg,
1.75 mmol) and 1 (253 mg, 1.75 mmol); filtered and washed with
EtOH to give 2e as a brown powder (284 mg, 67%); Rf 0.33 (25%
EtOAc in hexanes); mp 160−168 °C; 1H NMR (400 MHz, CDCl3) δ:
8.47 (s, 1H), 8.40 (s, 1H), 7.98 (s, 1H), 7.09 (d, J = 4.7 Hz, 1H), 4.01
(dt, J = 11.1 & 3.5 Hz, 2H), 3.47 (td, J = 11.5 & 2.2 Hz, 2H), 2.72−2.40
(m, 1H), 1.85−1.73 (m, 2H), 1.73−1.57 (m, 2H); 13C NMR (101
MHz, CDCl3) δ: 152.2, 148.3, 146.1, 133.8, 129.2, 67.3, 37.9, 30.1;m/z
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From S13 (175 mg, 0.75 mmol) and 1 (109 mg, 0.75 mmol) to give
2f as a light yellow powder (200 mg, 74%); carried forward without
further purification or characterization; Rf 0.26 (10% EtOAc in
hexanes).
2-Chloro-6-(2-((E)-((2r,3R,4r,5S)-4-iodocuban-1-yl)methylene)-
hydrazinyl) pyrazine (2g). From S15 (60.0 mg, 0.23 mmol) and 1
(33.6 mg, 0.23 mmol) to give 2g as an off-white powder (90.1 mg,
>100%); carried forward without further purification or character-
ization; Rf 0.73 (2% MeOH in CH2Cl2).
General Procedure for the Synthesis of 3a−g. The product
from General Procedure 1 (1 equiv) was stirred into CH2Cl2 (112
mM). PhI(OAc)2 (1 equiv) was added, and the reaction was stirred at rt
until completion, as indicated by TLC. The reaction was quenched with
sat. aq. NaHCO3, diluted with CH2Cl2, and the organic layer was
separated. The aqueous layer was extracted with CH2Cl2 (3×), and the
combined organic layers were washed with brine, dried (MgSO4),
filtered, and concentrated under reduced pressure to give the
corresponding crude material, which was purified by flash chromatog-
raphy on silica to give compounds 3a−g.
5-Chloro-3-(4-(difluoromethoxy)phenyl)-[1,2,4]triazolo[4,3-a]-
pyrazine (3a). From 2a (6.70 g, 22.4 mmol) to give the crude product,
which was purified by automated flash chromatography on silica
(Biotage Isolera, 12−100% EtOAc in hexanes) to give 3a as a reddish-
brown solid (4.91 g, 73%); Rf 0.42 (50% EtOAc in hexanes); mp 130−
133 °C; 1HNMR (300MHz, CDCl3) δ: 9.34 (s, 1H), 7.88 (s, 1H), 7.65
(d, J = 7.6 Hz, 2H), 7.27 (d, J = 7.7 Hz, 2H), 6.64 (t, J = 73.1 Hz, 1H);
13CNMR (75MHz, CDCl3) δ: 153.2, 147.4, 147.3, 143.2, 133.2, 130.0,
123.8, 122.0, 118.8, 115.6 (t, J = 261.4 Hz).
tert-Butyl 3-(5-Chloro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)-
pyrrolidine-1-carboxylate (3b). From 2b (160 mg, 0.49 mmol) to
give the crude product, which was purified by automated flash
chromatography on silica (Biotage Isolera, 12−100% EtOAc in
hexanes) to give 3b as a pale yellow powder (101 mg, 63%); Rf 0.07
(50% EtOAc in hexanes); mp 157−160 °C; 1H NMR (400 MHz,
CDCl3) δ: 9.23 (s, 1H), 7.84 (s, 1H), 4.45−4.32 (m, 1H), 4.00−3.70
(m, 3H), 3.55 (dt, J = 10.7 & 7.3 Hz, 1H), 2.90−2.50 (m, 1H), 2.54−
2.35 (m, 1H), 1.46 (s, 9H); 13C NMR (101 MHz, CDCl3) δ: 154.4,
149.3, 147.7, 143.3, 129.5, 121.3, 79.8, 51.4 (d, J = 57.4 Hz), 45.6, 36.7
(d, J = 85.9 Hz), 31.2 (d, J = 63.2 Hz), 28.6; m/z (ESI+) 346 ([M +




(3c). From 2c (600 mg, 2.65 mmol) to give the crude product, which
was purified by automated flash chromatography on silica (Biotage
Isolera, 12−100% EtOAc in hexanes) to give 3c as a pale yellow powder
(457 mg, 77%); Rf 0.06 (50% EtOAc in hexanes); mp 99−102 °C; 1H
NMR (400MHz, CDCl3) δ: 9.22 (s, 1H), 7.83 (s, 1H), 4.42 (dq, J = 8.7
& 6.3 Hz, 1H), 4.30 (dd, J = 8.5 & 7.3 Hz, 1H), 4.24−4.17 (m, 1H),
4.17−4.11 (m, 1H), 4.05 (td, J = 8.1 & 5.9 Hz, 1H), 2.77 (ddt, J = 12.2,
7.9 & 6.0 Hz, 1H), 2.48 (dddd, J = 12.5, 8.7, 7.8 & 6.5 Hz, 1H); 13C
NMR (101 MHz, CDCl3) δ: 149.8, 147.8, 143.4, 129.4, 121.3, 72.9,
68.6, 37.7, 32.4; m/z (ESI+) 247 ([M + Na]+, 100%); HRMS (ESI+)
found 225.0538 ([M + H]+), C9H9ClN4OH
+ requires 225.0538.
tert-Butyl 4-(5-Chloro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)-
piperidine-1-carboxylate (3d). From 2d (300 mg, 0.88 mmol) to
give the crude product, which was purified by automated flash
chromatography on silica (Biotage Isolera, 12−100% EtOAc in
hexanes) to give 3d as a pale yellow powder (245 mg, 82%); Rf 0.14
(50% EtOAc in hexanes); mp 112−116 °C; 1H NMR (400 MHz,
CDCl3) δ: 9.21 (s, 1H), 7.82 (s, 1H), 4.50 (d, J = 12.5 Hz, 1H), 4.16 (s,
1H), 3.81 (t, J = 10.8 Hz, 1H), 3.28 (t, J = 11.8 Hz, 1H), 2.88 (s, 1H),
2.31 (d, J = 13.2 Hz, 1H), 2.12 (qd, J = 12.8 & 3.6 Hz, 1H), 1.91 (dq, J =
9.7 & 3.0 Hz, 1H), 1.64 (q, J = 11.6 & 10.8 Hz, 1H), 1.44 (s, 9H); 13C
NMR (101 MHz, CDCl3) δ: 154.5, 150.2, 147.3, 143.3, 129.4, 121.6,
80.1, 35.6, 31.0, 28.6, 25.0; m/z (ESI+) 360 ([M + Na]+, 100%);




pyrazine (3e). From 2e (230mg, 0.96mmol) to give the crude product,
which was purified by automated flash chromatography on silica
(Biotage Isolera, 12−100% EtOAc in hexanes) to give 3e as pale yellow
crystalline powder (145 mg, 63%); Rf 0.06 (50% EtOAc in hexanes);
mp 185−193 °C; 1H NMR (400MHz, CDCl3) δ: 9.23 (s, 1H), 7.82 (s,
1H), 4.27−4.09 (m, 2H), 3.95 (tt, J = 11.3 & 3.7 Hz, 1H), 3.61 (td, J =
11.7 & 2.1Hz, 2H), 2.45−2.21 (m, 2H), 2.17−2.03 (m, 2H); 13CNMR
(101 MHz, CDCl3) δ: 151.9, 147.4, 143.4, 129.5, 121.4, 67.5, 34.3,
32.4; m/z (ESI+) 261 ([M + Na]+, 100%); HRMS (ESI+) found
239.0693 ([M + H]+), C10H11ClN4OH
+ requires 239.0694.
5-Chloro-3-(4-iodophenyl)-[1,2,4]triazolo[4,3-a]pyrazine (3f).
From 2f (200 mg, 0.56 mmol) to give the crude product, which was
purified by automated flash chromatography on silica (Biotage Isolera,
12−100% EtOAc in hexanes) to give 3f as a light brown powder (157
mg, 79%); carried forward without further characterization; Rf 0.42
(50% EtOAc in hexanes); mp decomposed >200 °C; 1H NMR (300
MHz, CDCl3) δ: 9.34 (s, 1H), 7.88 (dapp, J = 5.8 Hz, 3H), 7.37 (d, J =
7.9 Hz, 2H).
5-Chloro-3-(4-iodocuban-1-yl)-[1,2,4]triazolo[4,3-a]pyrazine
(3g). From 2g (80.0 mg, 0.21 mmol) to give the crude product, which
was purified by automated flash chromatography on silica (Biotage
Isolera, 0−10%MeOH in CH2Cl2) to give 3g as a brown powder (62.0
mg, 78%); Rf 0.37 (2% MeOH in CH2Cl2); mp decomposed>150 °C;
1H NMR (300 MHz, CDCl3) δ: 9.20 (s, 1H), 7.87 (s, 1H), 4.95−4.56
(m, 3H), 4.54−4.12 (m, 3H); 13C NMR (75 MHz, CDCl3) δ: 147.7,
142.8, 129.1, 120.9, 54.7, 53.0, 51.7, 50.4, 34.5; m/z (ESI+) 405 ([M +
Na]+, 100%); HRMS (ESI+) found 404.9375 ([M + Na]+),
C13H8ClIN4Na
+ requires 404.9374.
General Procedure for the Synthesis of 4−31.Nucleophile (1.0
equiv) was added to PhMe (168 mM) along with the product from
General Procedure 2 (1.0 equiv), KOH (3.0 equiv), and 18-crown-6
(0.1 equiv). The reaction was stirred at rt until completion, as indicated
by TLC. The reaction was diluted with H2O and then extracted with
EtOAc. The organic layers were washed with H2O until the aqueous
layer became neutral, followed by brine, dried (MgSO4), filtered, and
concentrated under reduced pressure to give the crude material, which
was purified by flash chromatography on silica to give compounds 4−
31.
3-(4-(Difluoromethoxy)phenyl)-5-phenoxy-[1,2,4]triazolo[4,3-a]-
pyrazine (4). From phenol (31.7 mg, 0.34 mmol) and 3a (100 mg, 0.34
mmol); the solvent was removed, and the residue was directly purified
by automated flash chromatography on silica (Biotage Isolera, 25−
100% EtOAc in hexanes) to give 4 as an off-white powder (44.9 mg,
38%); Rf 0.41 (100% EtOAc); mp 113−117 °C; 1H NMR (400 MHz,
CDCl3) δ: 9.12 (s, 1H), 7.72 (d, J = 8.7 Hz, 2H), 7.36 (t, J = 7.9 Hz,
2H), 7.25−7.19 (m, 2H), 7.15 (d, J = 8.6 Hz, 2H), 6.93 (d, J = 8.0 Hz,
2H), 6.54 (t, J = 73.3 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ: 153.1,
152.6 (t, J = 2.8 Hz), 148.2, 146.5, 142.7, 138.4, 132.3, 130.6, 126.5,
124.4, 118.8, 115.7 (t, J = 261.0 Hz), 114.2; 19F NMR (376 MHz,
CDCl3) δ: −81.36; m/z (ESI+) 377 ([M + Na]+, 100%); HRMS (ESI
+) found 355.0998 ([M + H]+), C18H12F2N4O2H
+ requires 355.1001.
5-(Benzyloxy)-3-(4-(difluoromethoxy)phenyl)-[1,2,4]triazolo[4,3-
a]pyrazine (5). From benzyl alcohol (70.0 μL, 0.67 mmol) and 3a (200
mg, 0.67 mmol) to give the crude product, which was purified by
automated flash chromatography on silica (Biotage Isolera, 25−100%
EtOAc in hexanes) to give 5 as a pale yellow powder (135 mg, 54%); Rf
0.08 (50% EtOAc in hexanes); mp 152−156 °C; 1H NMR (300 MHz,
CDCl3) δ: 9.02 (s, 1H), 7.58 (d, J = 8.5 Hz, 2H), 7.42 (s, 1H), 7.38−
7.22 (m, 3H), 7.07 (d, J = 7.3 Hz, 2H), 6.95 (d, J = 8.4 Hz, 2H), 6.46 (t,
J = 73.4 Hz, 1H), 5.19 (s, 2H); 13C NMR (75 MHz, CDCl3) δ: 152.4,
147.9, 146.5, 143.9, 136.7, 132.9, 132.5, 129.3, 128.8, 128.2, 124.5,
118.3, 115.7 (t, J = 260.4Hz), 108.9, 72.9;m/z (ESI+) 391 ([M+Na]+,




[4,3-a]pyrazine (6). From 2-phenylethanol (80.8 μL, 0.67 mmol) and
3a (200 mg, 0.67 mmol) to give the crude product, which was purified
by automated flash chromatography on silica (Biotage Isolera, 25−
100% EtOAc in hexanes) to give 6 as a pale yellow powder (189 mg,
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73%); Rf 0.10 (50% EtOAc in hexanes); mp 115−117 °C; 1H NMR
(500MHz, DMSO-d6) δ: 9.03 (s, 1H), 7.77 (d, J = 8.6 Hz, 2H), 7.59 (s,
1H), 7.36 (t, J = 73.7 Hz, 1H), 7.30 (d, J = 8.6 Hz, 2H), 7.20−7.13 (m,
3H), 6.97−6.84 (m, 2H), 4.50 (t, J = 6.4 Hz, 2H), 2.88 (t, J = 6.4 Hz,
2H); 13C NMR (126 MHz, DMSO-d6) δ: 152.0, 147.4, 145.5, 143.8,
137.3, 135.0, 132.6, 128.6, 128.2, 126.4, 124.7, 117.6, 116.1 (t, J = 258.2
Hz), 108.8, 71.2, 33.8; m/z (ESI+) 405 ([M + Na]+, 100%), 787 ([2M




triazolo[4,3-a]pyrazine (7). From 3-phenylpropanol (45.9 μL, 0.34
mmol) and 3a (100 mg, 0.34 mmol); the solvent was removed, and the
residue was directly purified by automated flash chromatography on
silica (Biotage Isolera, 25−100% EtOAc in hexanes) to give 7 as a dark
yellow crystalline powder (111 mg, 83%); Rf 0.42 (100% EtOAc); mp
153−157 °C; 1HNMR (400 MHz, CDCl3) δ: 9.03 (s, 1H), 7.75 (d, J =
8.8 Hz, 2H), 7.32−7.16 (m, 6H), 6.96 (d, J = 7.0 Hz, 2H), 6.47 (t, J =
73.3 Hz, 1H), 4.19 (t, J = 5.9 Hz, 2H), 2.35 (t, J = 7.6 Hz, 2H), 1.96 (dt,
J = 8.4 & 6.4 Hz, 2H); 13C NMR (101 MHz, CDCl3) δ: 152.7, 147.9,
146.3, 144.2, 140.0, 136.5, 132.6, 128.8, 128.3, 126.6, 125.2, 118.6,
115.7 (t, J = 261.0 Hz), 108.4, 70.1, 31.6, 29.9; 19F NMR (376 MHz,
CDCl3) δ: −81.33; m/z (ESI+) 419 ([M + Na]+, 100%); HRMS (ESI
+) found 397.1469 ([M + H]+), C21H18F2N4O2H
+ requires 397.1471.
5-(2-Cyclopropylethoxy)-3-(4-(difluoromethoxy)phenyl)-[1,2,4]-
triazolo[4,3-a]pyrazine (8). From 2-cyclopropylethanol (50.0 mg, 0.58
mmol) and 3a (172 mg, 0.58 mmol) to give the crude product, which
was purified by automated flash chromatography on silica (Biotage
Isolera, 25−100% EtOAc in hexanes) to give an orange solid; repurifed
by preparative TLC (75% EtOAc in hexanes) to give 8 as a yellow
powder (42.3 mg, 21%); Rf 0.58 (100% EtOAc); mp 120−124 °C; 1H
NMR (400MHz, CDCl3) δ: 9.03 (s, 1H), 7.71 (d, J = 8.8 Hz, 2H), 7.32
(s, 1H), 7.23 (d, J = 8.7 Hz, 2H), 6.60 (t, J = 73.2 Hz, 1H), 4.25 (t, J =
6.3 Hz, 2H), 1.51 (q, J = 6.4 Hz, 2H), 0.54−0.19 (m, 3H), -0.01−-0.10
(m, 2H); 13C NMR (101 MHz, CDCl3) δ: 152.5, 148.0, 146.4, 144.4,
136.2, 132.6, 125.1, 118.8, 115.7 (t, J = 261.4 Hz), 108.3, 71.3, 33.5, 7.4,
4.3; 19F NMR (376 MHz, CDCl3) δ: −81.43; m/z (ESI+) 369 ([M +
Na]+, 100%), 715 ([2M + Na]+, 35%); HRMS (ESI+) found 347.1313
([M + H]+), C17H16F2N4O2H
+ requires 347.1314.
3-(4-(Difluoromethoxy)phenyl)-5-(2-(oxetan-3-yl)ethoxy)-[1,2,4]-
triazolo[4,3-a]pyrazine (9). From S1 (35.0 mg, 0.34 mmol) and 3a
(102 mg, 0.34 mmol) to give the crude product, which was purified by
automated flash chromatography on silica (Biotage Isolera, 1−10%
MeOH in CH2Cl2) to give 9 as an orange powder (21.6 mg, 17%); Rf
0.06 (100% EtOAc); mp 110−114 °C; 1HNMR (400MHz, CDCl3) δ:
9.04 (s, 1H), 7.68 (d, J = 8.7 Hz, 2H), 7.30 (s, 1H), 7.25 (d, J = 7.5 Hz,
2H), 6.62 (t, J = 73.1 Hz, 1H), 4.21−3.96 (m, 1H), 3.91−3.71 (m, 1H),
3.65 (qapp, J = 7.7Hz, 1H), 3.48 (ddapp, J = 9.0& 7.0Hz, 1H), 3.34 (dd, J
= 9.1 & 4.7 Hz, 1H), 2.47 (hept, J = 7.1 Hz, 1H), 1.86 (dtd, J = 12.9, 8.1
& 5.2 Hz, 1H), 1.42 (td, J = 13.0 & 7.6 Hz, 1H); 13C NMR (101 MHz,
CDCl3) δ: 152.4, 147.8, 146.2, 144.0, 136.8, 132.4, 125.2, 119.0, 115.6
(t, J = 262.0 Hz), 108.4, 72.3, 69.8, 67.5, 38.3, 28.4; m/z (ESI+) 385
([M + Na]+, 100%), 747 ([2M + Na]+, 47%); HRMS (ESI+) found
385.1087 ([M + Na]+), C17H16F2N4O3Na
+ requires 385.1083.
6-(2-((3-(4-(Difluoromethoxy)phenyl)-[1,2,4]triazolo[4,3-a]-
pyrazin-5-yl)oxy)ethyl)-2-oxa-6-azaspiro[3.3]heptane (10). From 2-
[2-oxa-6-azaspiro[3.3]heptan-6-yl]ethan-1-ol (100 mg, 0.70 mmol)
and 3a (207 mg, 0.70 mmol) to give the crude product, which was
purified by automated flash chromatography on silica (Biotage Isolera,
1−10%MeOH in CH2Cl2) to give 10 as a light brown powder (145mg,
52%); Rf 0.07 (5% MeOH in CH2Cl2); mp 136−141 °C; 1H NMR
(400 MHz, CDCl3) δ: 9.03 (s, 1H), 7.75 (d, J = 8.8 Hz, 2H), 7.28 (s,
1H), 7.26 (d, J = 8.8 Hz, 2H), 6.64 (t, J = 73.0 Hz, 1H), 4.62 (s, 4H),
4.16 (t, J = 5.2 Hz, 2H), 3.09 (s, 4H), 2.58 (t, J = 5.2 Hz, 2H); 13CNMR
(101 MHz, CDCl3) δ: 152.2, 147.9, 146.3, 144.0, 136.7, 132.7, 125.1,
119.0, 115.5 (t, J = 262.4 Hz), 108.6, 81.0, 70.0, 64.2, 56.4, 39.5; m/z




[1,2,4]triazolo[4,3-a]pyrazine (11). From 1-(2-hydroxyethyl)-
pyrrolidine (59.1 μL, 0.51 mmol) and 3a (150 mg, 0.51 mmol); the
solvent was removed, and the residue was directly purified by
automated flash chromatography on silica (Biotage Isolera, 1−10%
MeOH in CH2Cl2) to give 11 as a brown powder (70.2 mg, 37%); Rf
0.12 (5% MeOH in CH2Cl2); mp 96−102 °C; 1H NMR (400 MHz,
CD3OD) δ: 8.98 (s, 1H), 7.80 (d, J = 8.8 Hz, 2H), 7.54 (s, 1H), 7.33 (d,
J = 8.8 Hz, 2H), 7.00 (t, J = 73.5 Hz, 1H), 4.43 (t, J = 5.2 Hz, 2H), 2.77
(t, J = 5.2 Hz, 2H), 2.32 (t, J = 6.5 Hz, 4H), 1.87−1.59 (m, 4H); 13C
NMR (101 MHz, CD3OD) δ: 151.9, 149.5, 149.1, 146.0, 136.3, 134.0,
125.9, 119.5, 117.4 (t, J = 259.5 Hz), 110.1, 71.3, 55.1, 54.6, 24.2; m/z




[1,2,4]triazolo[4,3-a]pyrazine (12). From 1-(2-hydroxyethyl)-
piperidine (67.1 μL, 0.51 mmol) and 3a (150 mg, 0.51 mmol); the
solvent was removed, and the residue was directly purified by
automated flash chromatography on silica (Biotage Isolera, 1−10%
MeOH in CH2Cl2) to give 12 as a brown powder (70.2 mg, 36%); Rf
0.21 (5% MeOH in CH2Cl2); mp 123−129 °C; 1H NMR (400 MHz,
CD3OD) δ: 8.97 (s, 1H), 7.79 (d, J = 8.7 Hz, 2H), 7.53 (s, 1H), 7.33 (d,
J = 8.7 Hz, 2H), 7.01 (t, J = 73.5 Hz, 1H), 4.43 (t, J = 5.1 Hz, 2H), 2.63
(t, J = 5.1 Hz, 2H), 2.21 (br sapp, 4H), 1.73−1.35 (m, 4H), 1.41−1.33
(m, 2H); 13C NMR (101 MHz, CD3OD) δ: 154.3, 149.0, 147.8, 146.0,
136.2, 133.9, 125.9, 119.4, 117.4 (t, J = 259.4 Hz), 110.1, 70.3, 57.7,
55.4, 26.5, 24.7; m/z (ESI+) 412 ([M + Na]+, 100%); HRMS (ESI+)
found 390.1737 ([M + H]+), C19H21F2N5O2H
+ requires 390.1736.
4-(2-((3-(4-(Difluoromethoxy)phenyl)-[1,2,4]triazolo[4,3-a]-
pyrazin-5-yl)oxy)ethyl)morpholine (13). From 4-(2-hydroxyethyl)-
morpholine (61.2 μL, 0.51 mmol) and 3a (150 mg, 0.51 mmol); the
solvent was removed, and the residue was directly purified by
automated flash chromatography on silica (Biotage Isolera, 1−10%
MeOH in CH2Cl2) to give 13 as a light brown powder (141 mg, 71%);
Rf 0.26 (5%MeOH in CH2Cl2); mp 160−164 °C; 1HNMR (400MHz,
CD3OD) δ: 8.97 (s, 1H), 7.80 (d, J = 8.8 Hz, 2H), 7.53 (s, 1H), 7.33 (d,
J = 8.7Hz, 2H), 7.00 (t, J = 73.5 Hz, 1H), 4.42 (t, J = 5.1Hz, 2H), 3.62−
3.42 (m, 4H), 2.61 (t, J = 5.0 Hz, 2H), 2.37−2.04 (m, 4H); 13C NMR
(101 MHz, CD3OD) δ: 154.3, 150.1, 149.0, 146.1, 136.2, 134.0, 125.9,
119.4, 117.5 (t, J = 259.3 Hz), 110.1, 70.2, 67.7, 57.5, 54.5;m/z (ESI+)





S2 (200 mg, 0.87 mmol) and 3a (258 mg, 0.87 mmol) to give the crude
product, which was purified by automated flash chromatography on
silica (Biotage Isolera, 2−20%MeOH in CH2Cl2) to give 14 as a yellow
powder with trace amounts of inseparable S2 (205 mg, 48%); Rf 0.01
(100% EtOAc); mp 134−139 °C; 1HNMR (400MHz, CDCl3) δ: 9.04
(s, 1H), 7.74 (d, J = 8.8 Hz, 2H), 7.32 (s, 1H), 7.24 (d, J = 8.8 Hz, 2H),
6.62 (t, J = 73.1 Hz, 1H), 4.30 (t, J = 5.2 Hz, 2H), 3.33−3.18 (m, 4H),
2.59 (t, J = 5.2 Hz, 2H), 2.25−2.05 (m, 4H), 1.45 (s, 9H); 13C NMR
(101 MHz, CDCl3) δ: 154.7, 152.4, 147.9, 146.4, 144.0, 136.7, 132.6,
125.1, 118.9, 115.6 (t, J = 262.0 Hz), 108.6, 80.0, 69.0, 56.1, 53.1, 28.5;
19F NMR (376 MHz, CDCl3) δ:−81.50;m/z (ESI+) 513 ([M + Na]+,
100%); HRMS (ESI+) found 491.2213 ([M + H]+), C23H28F2N6O4H
+
requires 491.2213.
3 - ( 4 - (D ifluo rome thox y ) pheny l ) - 5 - ( 2 - ( ( 1 R , 5 S ) - 6 , 6 -
dimethylbicyclo[3.1.1]hept-2-en-2-yl)ethoxy)-[1,2,4]triazolo[4,3-a]-
pyrazine (15). From (1R)-(−)-nopol (57.6 μL, 0.34 mmol) and 3a
(100 mg, 0.34 mmol); the solvent was removed, and the residue was
directly purified by automated flash chromatography on silica (Biotage
Isolera, 25−100% EtOAc in hexanes) to give 15 as a light red powder
(103 mg, 71%); Rf 0.49 (100% EtOAc); mp 134−137 °C; 1H NMR
(400 MHz, CDCl3) δ: 9.01 (s, 1H), 7.71 (d, J = 8.8 Hz, 2H), 7.29 (s,
1H), 7.24 (d, J = 8.8 Hz, 2H), 6.61 (t, J = 73.3 Hz, 1H), 4.97 (dt, J = 2.9
& 1.3 Hz, 1H), 4.29−4.11 (m, 2H), 2.39−2.22 (m, 3H), 2.13 (br s,
1H), 2.07 (br s, 1H), 2.05−1.98 (m, 1H), 1.83 (td, J = 5.7 & 1.5 Hz,
1H), 1.20 (s, 3H), 0.98 (dapp, J = 8.6 Hz, 1H), 0.63 (s, 3H);
13C NMR
(101 MHz, CDCl3) δ: 152.5, 148.0, 146.4, 144.1, 142.4, 136.4, 132.6,
125.1, 120.0, 118.7, 115.7 (t, J = 261.3 Hz), 108.4, 69.3, 45.5, 40.7, 38.1,
35.5, 31.7, 31.4, 26.3, 21.1; m/z (ESI+) 449 ([M + Na]+, 100%), 875
Journal of Medicinal Chemistry pubs.acs.org/jmc Article
https://dx.doi.org/10.1021/acs.jmedchem.0c00746
J. Med. Chem. 2020, 63, 11585−11601
11593





5-norbornene-2-methanol (40.8 μL, 0.34 mmol) and 3a (100 mg, 0.34
mmol); the solvent was removed, and the residue was directly purified
by automated flash chromatography on silica (Biotage Isolera, 25−
100% EtOAc in hexanes) to give 16 (present as a mixture of endo and
exo isomers) as a yellow powder (80.0 mg, 62%); Rf 0.63 (100%
EtOAc); mp 122−128 °C; 1H NMR (400 MHz, CDCl3, present as a
mixture of endo and exo isomers, ∼1:0.78 maj/min) δ: 9.01 (s,
1H(min)), 9.00 (s, 1H(maj)), 7.72 (d, J = 8.7 Hz, 4H(comb)), 7.37−7.14 (m,
6H(comb)), 6.61 (t, J = 73.2 Hz, 1H(min)), 6.59 (t, J = 73.2 Hz, 1H(maj)),
6.15 (dd, J = 5.7 & 3.0 Hz, 1H(maj)), 6.06 (dd, J = 5.7 & 3.0 Hz, 1H(min)),
5.90 (dd, J = 5.8 & 3.2 Hz, 1H(min)), 5.74 (dd, J = 5.7 & 2.8 Hz, 1H(maj)),
4.09 (ddd, J = 140.2, 8.8 & 6.2 Hz, 2H(min)), 3.88 (dt, J = 90.9 & 9.1 Hz,
2H(maj)), 2.89−2.65 (m, 2H(comb)), 2.43−2.20 (m, 3H(comb)), 1.71 (ddd,
J = 12.4, 9.1 & 3.7 Hz, 1H(maj)), 1.64 (dq, J = 9.5 & 4.8 Hz, 1H(min)),
1.47−1.35 (m, 1H(comb)), 1.34−1.23 (m, 1H(comb)), 1.21−1.12 (m,
3H(comb)), 1.10−0.99 (m, 1H(min)), 0.47 (ddd, J = 11.7, 4.1 & 2.6 Hz,
1H(maj)); 13C NMR (101MHz, CDCl3, present as a mixture of endo and
exo isomers) δ: 152.4, 152.3, 147.9, 146.3, 146.3, 144.24, 144.22, 138.6,
137.3, 136.3, 136.1, 135.7, 132.6, 132.5, 131.5, 129.1, 128.7, 125.3,
125.1, 119.1, 118.7, 115.7 (t, J = 261.6 Hz), 115.6 (t, J = 261.9 Hz),
108.2, 75.0, 74.4, 49.4, 44.8, 43.7, 43.4, 42.3, 41.6, 38.1, 37.9, 29.4, 28.9;
m/z (ESI+) 407 ([M + Na]+, 100%); HRMS (ESI+) found 407.1294
([M + Na]+), C20H18F2N4O2Na
+ requires 407.1290.
5-(((3r,5r,7r)-Adamantan-1-yl)methoxy)-3-(4-(difluoromethoxy)-
phenyl)-[1,2,4]triazolo[4,3-a]pyrazine (17). From 1-adamantaneme-
thanol (100 mg, 0.60 mmol) and 3a (178 mg, 0.60 mmol) to give the
crude product, which was purified by automated flash chromatography
on silica (Biotage Isolera, 25−100% EtOAc in hexanes) to give 17 as a
yellow powder (140 mg, 55%); Rf 0.53 (100% EtOAc); mp 210−219
°C; 1H NMR (400 MHz, CDCl3) δ: 9.01 (s, 1H), 7.67 (d, J = 8.7 Hz,
2H), 7.29 (s, 1H), 7.26 (d, J = 8.7 Hz, 2H), 6.59 (t, J = 73.2 Hz, 1H),
3.71 (s, 2H), 1.88 (br s, 3H), 1.67 (d, J = 12.3 Hz, 3H), 1.48 (d, J = 11.6
Hz, 3H), 1.26 (dapp, J = 2.5 Hz, 6H);
13C NMR (101 MHz, CDCl3) δ:
152.6, 147.9, 146.0, 144.9, 136.2, 132.4, 125.5, 118.9, 115.7 (t, J = 261.2
Hz), 108.7, 81.6, 38.8, 36.6, 33.6, 27.8; m/z (ESI+) 449 ([M + Na]+,




phenyl)-[1,2,4]triazolo[4,3-a]pyrazine (18). From 1-adamantaneetha-
nol (250mg, 1.39mmol) and 3a (411mg, 1.39mmol) to give the crude
product, which was purified by automated flash chromatography on
silica (Biotage Isolera, 25−100% EtOAc in hexanes) to give 18 as a light
brown powder (363 mg, 59%); Rf 0.63 (100% EtOAc); mp 182−185
°C; 1H NMR (400 MHz, CDCl3) δ: 9.00 (s, 1H), 7.73−7.64 (m, 2H),
7.29 (s, 1H), 7.25−7.20 (m, 2H), 6.61 (t, J = 73.2 Hz, 1H), 4.24 (t, J =
6.7 Hz, 2H), 1.87 (s, 3H), 1.66 (d, J = 12.3 Hz, 3H), 1.52 (d, J = 11.4
Hz, 3H), 1.39 (t, J = 6.7 Hz, 2H), 1.29 (d, J = 2.4 Hz, 6H); 13C NMR
(101 MHz, CDCl3) δ: 152.5, 147.9, 146.4, 144.2, 136.2, 132.7, 125.1,
118.7, 115.6 (t, J = 261.6 Hz), 108.3, 67.5, 42.3, 41.9, 36.8, 31.7, 28.5;
m/z (ESI+) 463 ([M + Na]+, 100%); HRMS (ESI+) found 463.1916
([M + Na]+), C24H26F2N4O2Na
+ requires 463.1916.
5-(2-(Cuban-1-yl)ethoxy)-3-(4-(difluoromethoxy)phenyl)-[1,2,4]-
triazolo[4,3-a]pyrazine (19). From 2-cubylethan-1-ol57 (19.0 mg, 0.12
mmol) and 3a (37.0 mg, 0.12 mmol) to give the crude product, which
was purified by automated flash chromatography on silica (Biotage
Isolera, 18−100% EtOAc in hexanes) to give 19 as a pale yellow powder
(28.0 mg, 55%); Rf 0.35 (75% EtOAc in hexanes); mp 146−149 °C; 1H
NMR (300MHz, CDCl3) δ: 9.05 (s, 1H), 7.73 (d, J = 8.7 Hz, 2H), 7.33
(s, 1H), 7.24 (d, J = 8.6 Hz, 2H), 6.61 (t, J = 73.2 Hz, 1H), 4.26 (t, J =
6.5 Hz, 2H), 3.98 (ddq, J = 7.2, 4.6 & 2.2 Hz, 1H), 3.78 (q, J = 5.0 Hz,
3H), 3.54 (ddd, J = 5.7, 4.4 & 2.3 Hz, 3H), 1.95 (t, J = 6.5 Hz, 2H); 13C
NMR (75 MHz, CDCl3) δ: 152.5, 147.9, 146.4, 144.2, 136.3, 132.7,
124.9, 119.1, 118.6, 115.7, 112.2, 108.4, 68.2, 55.7, 48.6, 48.3, 44.3,
31.8; m/z (ESI+) 431 ([M + Na]+, 100%), 839 ([2M + Na]+, 23%);




[1,2,4]triazolo[4,3-a]pyrazine (20). From S3 (20.0 mg, 0.12 mmol)
and 3a (37.0 mg, 0.12 mmol) to give the crude product, which was
purified by automated flash chromatography on silica (Biotage Isolera,
18−100% EtOAc in hexanes) to give 20 as a light brown powder (24.0
mg, 47%); Rf 0.33 (75% EtOAc in hexanes); mp 128−132 °C; 1HNMR
(300 MHz, CDCl3) δ: 9.06 (s, 1H), 7.72 (d, J = 8.7 Hz, 2H), 7.32 (s,
1H), 7.23 (d, J = 8.5 Hz, 2H), 6.59 (t, J = 73.2 Hz, 1H), 4.22 (t, J = 6.2
Hz, 2H), 4.04 (qt, J = 4.5 & 2.2 Hz, 1H), 3.86 (q, J = 5.1 Hz, 3H), 3.63
(dt, J = 5.4 & 2.3 Hz, 3H), 1.75 (s, 4H); 13CNMR (75MHz, CDCl3) δ:
152.6, 147.9, 146.3, 144.3, 136.3, 132.5, 125.1, 119.2, 118.6, 115.7,
112.2, 108.4, 71.4, 58.2, 48.7, 48.2, 44.1, 29.1, 23.6; m/z (ESI+) 445
([M + Na]+, 100%), 867 ([2M + Na]+, 13%); HRMS (ESI+) found




triazolo[4,3-a]pyrazine (21). From S7 (20.0 mg, 0.11 mmol) and 3a
(31.2 mg, 0.11 mmol); the solvent was removed, and the residue was
directly purified by automated flash chromatography on silica (Biotage
Isolera, 25−100%EtOAc in hexanes) to give 21 as a light brown powder
(14.5 mg, 31%); Rf 0.35 (100% EtOAc); mp 136−142 °C; 1H NMR
(400 MHz, CDCl3) δ: 9.02 (s, 1H), 7.70 (d, J = 8.8 Hz, 2H), 7.29 (s,
1H), 7.23 (d, J = 8.7 Hz, 2H), 6.61 (t, J = 73.2 Hz, 1H), 4.18 (tq, J = 5.8
& 2.5 Hz, 2H), 2.60 (q, J = 6.5 Hz, 1H), 2.48 (dq, J = 27.4 & 6.8 Hz,
2H), 2.30 (dt, J = 7.8 & 4.0 Hz, 1H), 2.25−2.19 (m, 1H), 2.19−2.13
(m, 1H), 2.01−1.97 (m, 1H), 1.91 (q, J = 6.5 Hz, 2H), 1.68−1.49 (m,
4H), 1.18−1.05 (m, 2H); 13C NMR (101 MHz, CDCl3) δ: 148.0,
146.4, 145.8, 144.3, 136.3, 132.5, 125.1, 118.6, 115.7, 108.4, 71.2, 47.4,
47.0, 44.5, 42.3, 41.8, 41.5, 38.8, 38.4, 36.3, 34.2, 28.7, 28.6;m/z (ESI+)





From S8 (15.0 mg, 101 μmol) and 3a (30.0 mg, 101 μmol); the
solvent was removed, and the residue was directly purified by
automated flash chromatography on silica (Biotage Isolera, 25−100%
EtOAc in hexanes) to give 22 as a yellow powder (11.1 mg, 27%); Rf
0.40 (100% EtOAc); mp 129−134 °C; 1HNMR (500MHz, CDCl3) δ:
9.05 (s, 1H), 7.69 (d, J = 8.8 Hz, 2H), 7.29 (d, J = 8.7 Hz, 2H), 7.28 (s,
1H), 6.61 (t, J = 73.0 Hz, 1H), 5.62 (t, J = 56.3 Hz, 1H), 4.20 (s, 2H),
1.63 (s, 6H); 13C NMR (126 MHz, CDCl3) δ: 152.2, 147.8, 146.1,
144.2, 136.8, 132.4, 125.5, 119.5, 115.6, 112.6, 108.5, 70.4, 47.6 (t, J =
3.9 Hz), 39.0, 37.2; m/z (ESI+) 431 ([M + Na]+, 100%); HRMS (ESI
+) found 409.1281 ([M + H]+), C19H16F4N4O2H
+ requires 409.1282.
5-( (1 ,2-Dicarba-closo-decaborane-1-y l )ethoxy)-3- (4-
(difluoromethoxy)phenyl)-[1,2,4]triazolo[4,3-a]pyrazine (23). From
S9 (50.0 mg, 0.27 mmol) and 3a (78.8 mg, 0.27 mmol) to give the
crude product, which was purified by automated flash chromatography
on silica (Biotage Isolera, 25−100% EtOAc in hexanes) to give 23 as a
light brown powder (43.6 mg, 37%); Rf 0.17 (100% EtOAc); mp 179−
184 °C; 1H NMR (400 MHz, CDCl3) δ: 9.10 (s, 1H), 7.69 (d, J = 8.8
Hz, 2H), 7.33 (s, 1H), 7.29 (d, J = 8.7 Hz, 2H), 6.66 (t, J = 72.7 Hz,
1H), 4.32 (t, J = 5.6 Hz, 2H), 2.55 (t, J = 5.6 Hz, 2H), 3.11−1.14 (m,
11H); 13C NMR (101 MHz, CDCl3) δ: 152.6, 147.9, 145.8, 142.9,
137.8, 132.5, 124.8, 119.3, 115.4 (t, J = 263.3 Hz), 108.7, 71.0, 68.5,
60.1, 36.4;m/z (ESI+) 449 ([M +H]+, 20%), 471 ([M +Na]+, 100%);
HRMS (ESI+) found 471.2610 ([M + Na]+), C16H22B10F2N4O2Na
+
requires 471.2614.
5-( (1 ,7-Dicarba-closo-decaborane-1-y l )ethoxy)-3- (4-
(difluoromethoxy)phenyl)-[1,2,4]triazolo[4,3-a]pyrazine (24). From
S10 (20.0 mg, 106 μmol) and 3a (31.5 mg, 106 μmol) the solvent was
removed, and the residue was directly purified by automated flash
chromatography on silica (Biotage Isolera, 25−100% EtOAc in
hexanes) to give a yellow powder (11.1 mg, 23%); repurified by
automated reversed-phase flash chromatography on silica (Biotage
Isolera, 5−100% MeOH in H2O) to give 24 as a light yellow powder
(8.3 mg, 17%); Rf 0.36 (100% EtOAc); mp 158−162 °C; 1H NMR
(400MHz, CDCl3) δ: 9.07 (s, 1H), 7.69 (d, J = 8.7 Hz, 2H), 7.31−7.24
(m, 3H), 6.63 (t, J = 73.1 Hz, 1H), 4.16 (t, J = 6.5 Hz, 2H), 2.25 (t, J =
6.5 Hz, 2H), 3.28−0.98 (m, 11H); 13C NMR (101 MHz, CDCl3) δ:
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152.6, 147.9, 146.3, 143.3, 137.4, 132.5, 125.0, 119.2, 115.6 (t, J = 262.0
Hz), 108.7, 71.2, 68.9, 55.5, 34.8; 19F NMR (376 MHz, CDCl3) δ:
−81.47; m/z (ESI+) 471 ([M + Na]+, 100%); HRMS (ESI+) found




S12 (20.0 mg, 106 μmol) and 3a (31.5 mg, 106 μmol); the solvent was
removed, and the residue was directly purified by automated flash
chromatography on silica (Biotage Isolera, 25−100% EtOAc in
hexanes) to give 25 as a light brown powder (16.2 mg, 34%); Rf 0.43
(100% EtOAc); mp 137−143 °C; 1HNMR (500MHz, CDCl3) δ: 9.05
(s, 1H), 7.65 (d, J = 8.7 Hz, 2H), 7.25 (d, J = 8.8 Hz, 1H), 7.23 (s, 1H),
6.63 (t, J = 73.1 Hz, 1H), 3.98 (t, J = 6.6 Hz, 2H), 1.91 (t, J = 6.6 Hz,
2H), 2.86−1.05 (m, 11H); 13C NMR (126 MHz, CDCl3) δ: 152.6,
147.9, 146.4, 143.3, 137.2, 132.5, 124.9, 119.0, 115.7 (t, J = 261.7 Hz),
108.6, 70.8, 68.6, 59.2, 36.4; m/z (ESI+) 449 ([M + H]+, 100%);




pyrrolidine-1-carboxylate (26). From 2-phenylethanol (25.9 μL,
0.22 mmol) and 3b (70.0 mg, 0.22 mmol); the solvent was removed,
and the residue was directly purified by automated flash chromatog-
raphy on silica (Biotage Isolera, 25−100%EtOAc in hexanes) to give 26
as a pale yellow powder (38.7 mg, 44%); Rf 0.14 (100% EtOAc); mp
123−126 °C; 1H NMR (400 MHz, CDCl3) δ: 8.91 (s, 1H), 7.47−7.04
(m, 6H), 4.60 (dapp, J = 17.1 Hz, 2H), 3.79 (dapp, J = 7.0 Hz, 2H), 3.69
(s, 1H), 3.40 (br s, 1H), 3.27 (t, J = 7.0 Hz, 2H), 2.67 (br s, 1H), 2.38
(br s, 1H), 2.16 (br s, 1H), 1.49 (s, 9H); 13C NMR (126MHz, CDCl3)
δ: 154.6, 154.4, 148.1, 147.9, 147.8, 144.1, 136.8, 136.7, 136.2, 136.1,
129.2, 129.1, 128.6, 128.5, 127.6, 127.5, 108.0, 107.9, 79.7, 71.0, 51.5,
50.9, 45.7, 45.4, 37.0, 36.2, 35.12, 35.07, 30.9, 30.3, 28.7 (mixture of
amide rotamers); m/z (ESI+) 432 ([M + Na]+, 100%); HRMS (ESI+)
found 432.2000 ([M + Na]+), C22H27N5O3Na
+ requires 432.2006.
5-Phenethoxy-3-(tetrahydrofuran-3-yl)-[1,2,4]triazolo[4,3-a]-
pyrazine (27). From 2-phenylethanol (107 μL, 0.89 mmol) and 3c
(200 mg, 0.89 mmol); the solvent was removed, and the residue was
directly purified by automated flash chromatography on silica (Biotage
Isolera, 25−100% EtOAc in hexanes) to give 27 as a yellow powder
(205 mg, 74%); Rf 0.11 (100% EtOAc); mp 127−133 °C; 1H NMR
(400 MHz, CDCl3) δ: 8.91 (s, 1H), 7.41−7.33 (m, 2H), 7.30 (td, J =
8.3, 7.8 & 4.0Hz, 3H), 7.25 (s, 1H), 4.89−4.48 (m, 2H), 4.37−3.73 (m,
5H), 3.27 (t, J = 6.6 Hz, 2H), 2.86−2.47 (m, 1H), 2.31−2.10 (m, 1H);
13C NMR (101 MHz, CDCl3) δ: 148.5, 147.9, 144.1, 136.8, 136.2,
129.2, 128.7, 127.6, 107.8, 72.7, 71.1, 68.5, 37.6, 35.1, 31.8;m/z (ESI+)




piperidine-1-carboxylate (28). From 2-phenylethanol (70.9 μL, 0.59
mmol) and 3d (200 mg, 0.59 mmol); the solvent was removed, and the
residue was directly purified by automated flash chromatography on
silica (Biotage Isolera, 25−100% EtOAc in hexanes) to give 28 as a pale
yellow powder (174 mg, 69%); Rf 0.26 (100% EtOAc); mp 145−149
°C; 1H NMR (400 MHz, CDCl3) δ: 8.89 (s, 1H), 7.56−7.10 (m, 6H),
4.80−4.41 (m, 2H), 4.26−4.04 (m, 1H), 3.56−3.40 (m, 1H), 3.37−
3.15 (m, 2H), 2.87 (t, J = 12.2 Hz, 2H), 2.13 (dapp, J = 10.7 Hz, 2H),
1.86 (dq, J = 9.3 & 2.8 Hz, 1H), 1.59−1.39 (m, 2H), 1.46 (s, 9H); 13C
NMR (101 MHz, CDCl3) δ: 154.7, 149.0, 147.5, 144.3, 136.5, 129.0,
128.9, 127.3, 107.8, 79.9, 71.4, 48.7, 44.7, 35.5, 34.7, 28.6, 25.2; m/z




a]pyrazine (29). From 2-phenylethanol (50.2 μL, 0.42 mmol) and 3e
(100 mg, 0.42 mmol); the solvent was removed, and the residue was
directly purified by automated flash chromatography on silica (Biotage
Isolera, 25−100% EtOAc in hexanes) to give 29 as a pale yellow powder
(95.2 mg, 70%); Rf 0.10 (100% EtOAc); mp 146−149 °C; 1H NMR
(400MHz, CDCl3) δ: 8.92 (s, 1H), 7.42−7.35 (m, 2H), 7.33−7.26 (m,
4H), 4.62 (t, J = 6.7 Hz, 2H), 4.37−3.87 (m, 2H), 3.53 (tt, J = 11.4 &
3.8 Hz, 1H), 3.37 (td, J = 11.7 & 2.1 Hz, 2H), 3.29 (t, J = 6.6 Hz, 2H),
2.24−2.06 (m, 2H), 1.95−1.78 (m, 2H); 13CNMR (101MHz, CDCl3)
δ: 150.9, 147.6, 144.2, 136.9, 136.0, 129.2, 128.6, 127.6, 107.8, 70.6,
67.5, 34.8, 34.2, 32.0; m/z (ESI+) 347 ([M + Na]+, 100%); HRMS




a]pyrazine (30). From 2-(3,4-difluorophenyl)ethanol (44.4 mg, 0.28
mmol) and 3f (100 mg, 0.28 mmol) to give the crude product, which
was purified by automated flash chromatography on silica (Biotage
Isolera, 25−100% EtOAc in hexanes) to give 30 as a pale yellow powder
(81.1 mg, 61%); Rf 0.50 (100% EtOAc); mp 155−157 °C; 1H NMR
(300MHz, CDCl3) δ: 9.02 (s, 1H), 7.83 (d, J = 7.7Hz, 2H), 7.40 (d, J =
7.6 Hz, 2H), 7.31 (s, 1H), 7.00 (q, J = 8.7 Hz, 1H), 6.54 (t, J = 9.2 Hz,
2H), 4.42 (t, J = 5.9 Hz, 3H), 2.92 (t, J = 5.8 Hz, 3H); 13C NMR (101
MHz, CDCl3) δ: 150.3 (dd, J = 249.0 & 12.7 Hz), 149.5 (dd, J = 248.0
& 12.5 Hz), 147.9, 146.3, 143.8, 137.1, 136.8, 133.3 (dd, J = 5.6 & 4.0
Hz), 132.3, 127.4, 124.5 (dd, J = 6.1 & 3.6 Hz), 117.5 (d, J = 17.4 Hz),
117.4 (d, J = 17.3 Hz), 108.5, 96.7, 70.9, 33.9; m/z (ESI+) 501 ([M +




[4,3-a]pyrazine (31). From 2-(3,4-dilfuorophenyl)ethanol (20.7 mg,
0.13 mmol) and 3g (50.0 mg, 0.13 mmol) to give the crude product,
which was purified by automated flash chromatography on silica
(Biotage Isolera, 25−100% EtOAc in hexanes) to give 31 as a brown
powder (19.9 mg, 30%); Rf 0.23 (100% EtOAc); mp 147−153 °C; 1H
NMR (300 MHz, CDCl3) δ: 8.86 (s, 1H), 7.47−6.73 (m, 4H), 4.64−
4.35 (m, 5H), 4.26 (s, 3H), 3.16 (t, J = 7.5 Hz, 2H); 13C NMR (75
MHz, CDCl3) δ: 148.3, 146.3, 143.3, 136.7, 132.2, 125.0, 118.3, 118.0,
117.8, 108.1, 74.1, 71.4, 54.9, 52.2, 35.4, 34.2, 29.8; m/z (ESI+) 527




[1,2,4]triazolo[4,3-a]pyrazine (32). Compound 14 (150 mg, 0.31
mmol, 1.00 equiv) was dissolved in CH2Cl2 (0.88 mL). TFA (0.26 mL,
3.42 mmol, 11.2 equiv) was added, and the reaction was stirred at rt
overnight. The solvent was removed, and the residue was directly
purified by automated flash chromatography on silica (Biotage Isolera,
2−15%MeOH in CH2Cl2) to give 32 as a light yellow powder (106mg,
89%); mp 140−148 °C; 1HNMR (400MHz, CD3OD) δ: 8.99 (s, 1H),
7.81 (d, J = 8.8 Hz, 2H), 7.53 (s, 1H), 7.35 (d, J = 8.7 Hz, 2H), 7.03 (t, J
= 73.5 Hz, 1H), 4.42 (t, J = 5.0 Hz, 2H), 3.16−2.94 (m, 4H), 2.70 (t, J =
5.0 Hz, 2H), 2.58−2.35 (m, 4H) (amine NH signal not seen); 13C
NMR (101 MHz, CD3OD) δ: 154.2, 149.0, 147.8, 146.0, 136.3, 134.0,
126.0, 119.4, 117.4 (t, J = 259.5 Hz), 110.1, 70.1, 56.6, 50.6, 44.8; m/z




(33). Compound 26 (20.0 mg, 48.8 μmol, 1.00 equiv) was dissolved in
CH2Cl2 (0.13 mL). TFA (42.1 μL, 0.55 mmol, 11.2 equiv) was added,
and the reaction was stirred at rt overnight. The solvent was removed,
and the residue was directly purified by automated flash chromatog-
raphy on silica (Biotage Isolera, 2−10% MeOH in CH2Cl2) to give a
clear oil; repurified by automated reversed-phase flash chromatography
on silica (Biotage Isolera, 5−100%MeOH inH2O) to give 33 as a white
powder (9.1 mg, 60%); mp 78−85 °C; 1HNMR (400MHz, CDCl3) δ:
8.88 (s, 1H), 7.40−7.33 (m, 2H), 7.33−7.26 (m, 3H), 7.23 (s, 1H),
4.59 (t, J = 6.6 Hz, 2H), 3.86 (ddt, J = 8.7, 7.5 & 3.6 Hz, 1H), 3.27 (t, J =
6.6 Hz, 2H), 3.30−3.17 (m, 2H), 3.00 (dq, J = 41.7 & 7.5 Hz, 2H), 2.45
(br s, 1H), 2.34−2.18 (m, 1H), 2.16−1.94 (m, 1H); 13C NMR (101
MHz, CDCl3) δ: 150.7, 147.8, 144.3, 136.7, 136.3, 129.1, 128.7, 127.5,
107.7, 70.9, 53.6, 47.4, 37.9, 35.1, 32.6; m/z (ESI+) 310 ([M + H]+,




(34). Compound 28 (100 mg, 0.24 mmol, 1.00 equiv) was dissolved in
CH2Cl2 (0.62 mL). TFA (0.2 mL, 2.64 mmol, 11.2 equiv) was added,
and the reaction was stirred at rt overnight. The solvent was removed,
and the residue was directly purified by automated flash chromatog-
raphy on silica (Biotage Isolera, 210% MeOH in CH2Cl2) to give a
white solid; repurified by automated reversed-phase flash chromatog-
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raphy on silica (Biotage Isolera, 5−100%MeOH inH2O) to give 34 as a
white powder (61.7 mg, 81%); mp 175−180 °C; 1H NMR (400 MHz,
CDCl3) δ: 8.90 (s, 1H), 7.48−6.67 (m, 6H), 4.77−4.40 (m, 2H), 4.04
(dt, J = 8.1 & 4.4 Hz, 1H), 3.68−3.51 (m, 2H), 3.39−3.23 (m, 3H),
3.09 (ddd, J = 12.5, 9.0 & 4.1 Hz, 1H), 2.33−1.90 (m, 1H), 1.90−1.64
(m, 3H) (amine NH signal not seen); 13C NMR (101 MHz, CDCl3) δ:
147.5, 147.4, 143.9, 136.4, 136.0, 129.1, 128.7, 127.4, 108.5, 71.2, 46.9,
44.1, 34.5, 32.0, 29.2, 21.1;m/z (ESI+) 324 ([M +H]+, 100%); HRMS




pyrazine (35). From the late-stage biofunctionalization of 16; 1HNMR
(600MHz, DMSO-d6) δ: 9.05 (s, 1H), 7.81 (d, J = 8.8 Hz, 2H), 7.57 (s,
1H), 7.35 (t, J = 73.1 Hz, 1H), 7.34 (d, J = 8.7 Hz, 2H), 4.31−4.13 (m,
2H), 3.13 (d, J = 3.5Hz, 1H), 3.09 (d, J = 2.7Hz, 1H), 2.35 (br d, J = 2.5
Hz, 1H), 2.16−2.09 (m, 1H), 1.89−1.78 (m, 1H), 1.46 (ddd, J = 12.6,
10.2, 4.3 Hz, 1H), 1.09−1.02 (m, 1H), 0.73 (ddd, J = 12.6, 4.8, 2.5 Hz,





pyrazine (36). From the late-stage biofunctionalization of 16; 1HNMR
(600MHz, DMSO-d6) δ: 9.04 (s, 1H), 7.81 (d, J = 8.7 Hz, 2H), 7.52 (s,
1H), 7.37 (d, J = 8.6 Hz, 2H), 7.37 (t, J = 73.6 Hz, 1H), 4.19−3.96 (m,
2H), 3.08 (d, J = 3.8 Hz, 1H), 2.84 (d, J = 3.5 Hz, 1H), 2.34−2.26 (m,
1H), 1.91−1.78 (m, 1H), 1.72−1.60 (m, 1H), 1.25 (ddd, J = 11.1, 8.5,
2.3 Hz, 1H), 0.98 (dt, J = 12.7, 4.2 Hz, 1H), 0.94 (d, J = 10.1 Hz, 1H),




pyrazin-5-yl)oxy)ethyl)cuban-1-ol (37). From the late-stage bio-
functionalization of 19; 1H NMR (600 MHz, DMSO-d6) δ: 9.05 (s,
1H), 7.82 (d, J = 8.6 Hz, 2H), 7.58 (s, 1H), 7.36 (t, J = 73.7 Hz, 1H),
7.31 (d, J = 8.5 Hz, 2H), 6.02 (s, 1H), 4.30 (t, J = 6.2 Hz, 2H), 3.81 (dq,
J = 5.5, 2.7 Hz, 1H), 3.41 (dt, J = 5.1, 2.5 Hz, 2H), 3.37 (q, J = 5.1 Hz,
2H), 1.85 (t, J = 6.2 Hz, 2H). One cubane C−H at δ 3.33 obscured by




pyrazin-5-yl)oxy)ethyl)cuban-1-ol (38). From the late-stage bio-
functionalization of 19; 1H NMR (600 MHz, DMSO-d6) δ: 9.04 (s,
1H), 7.82 (d, J = 8.6 Hz, 2H), 7.58 (s, 1H), 7.37 (t, J = 73.7 Hz, 1H),
7.31 (d, J = 8.6 Hz, 2H), 6.15 (s, 1H), 4.32 (t, J = 6.0 Hz, 2H), 3.58 (t, J
= 5.2 Hz, 3H), 3.13 (t, J = 5.2 Hz, 3H), 1.89 (t, J = 6.0 Hz, 2H); HRMS





ted from the procedure of Yoo et al.:58 Compound 23 (20.0 mg, 44.6
μmol, 1 equiv) and CsF (20.3 mg, 134 μmol, 3 equiv) were dissolved in
EtOH (1 mL) and heated at reflux for 25 h. The solvent was removed.
Acetone (2 mL) was added, the solution was filtered through a fritted
glass funnel, washed several times with acetone, and the solvent was
removed to give the crude product as an off-white solid; purified by
automated flash chromatography on silica (Biotage Isolera, 2−10%
MeOH in CH2Cl2) to give 39 as a yellow powder (16.4 mg, 65%); Rf
0.13 (10% MeOH in CH2Cl2); mp 181−190 °C; 1H NMR (500 MHz,
CDCl3) δ: 8.94 (s, 1H), 7.76 (d, J = 8.9 Hz, 2H), 7.50 (s, 1H), 7.28 (d, J
= 8.9 Hz, 2H), 6.91 (t, J = 73.8 Hz, 1H), 4.56 (s, 2H), 4.46−4.29 (m,
2H), 1.94−1.65 (m, 2H) (carborane BH signals not seen); 13C NMR
(126 MHz, CD3OD) δ: 154.6, 149.0, 148.0, 146.3, 135.6, 133.9, 125.6,
119.2, 117.7 (t, J = 257.9Hz), 109.9, 74.2, 38.8 (carborane C signals not
seen); m/z (ESI+) 484 ([M+2Na]+, 100%); HRMS (ESI+) found
484.2381 ([M+2Na]+), C16H22B9CsF2N4O2Na2
+ requires 484.2375.
2-(Oxetan-3-yl)ethan-1-ol (S1). Lithium 2-(oxetan-3-yl)acetate
(150 mg) was converted to the free acid by addition of conc. HCl
and extraction with EtOAc to give a colorless oil (125 mg). The free
acid (100 mg, 0.86 mmol, 1 equiv) was dissolved in anhydrous THF (2
mL) and cooled to 0 °C. LiAlH4 (1 M in THF, 0.55 mL, 0.55 mmol,
0.64 equiv) was added dropwise, and the reaction mixture was stirred
for 10 min at 0 °C and then at rt. The reaction was cooled in an ice bath,
and the LAHwas quenched with EtOAc dropwise. A sat. aq. solution of
Rochelle’s salt was added, and the mixture was stirred at 0 °C and then
at rt for 1.5 h. The organic layer was separated, and the aqueous layer
was extracted with EtOAc (2×). The combined organic layers were
dried (MgSO4), filtered, and concentrated under reduced pressure to
give S1 as a yellow oil (41.4 mg, 47%); carried forward without further
purification or characterization.
tert-Butyl 4-(2-Hydroxyethyl)piperazine-1-carboxylate (S2). Fol-
lowing the procedure of del Prado et al.:59 A solution of Boc2O (2.18
mL, 9.45 mmol, 1.23 equiv) in CH2Cl2 (7mL) was added dropwise to a
solution of 1-(2-hydroxyethyl)piperazine (1.00 g, 7.68 mmol, 1.00
equiv) in CH2Cl2 (10 mL) at 0 °C. The reaction was warmed to rt and
stirred for 2 h. Sat. aq. NH4Cl (6 mL) was added, and the organic layer
was separated. The aqueous layer was extracted with CH2Cl2 (2 × 8
mL), and the combined organic layers were dried (Na2SO4), filtered,
and concentrated under reduced pressure to give the crude product;
purified by DCVC (25−100% EtOAc in hexanes) to give S2 as a clear
oil that crystallized on standing (674 mg, 38%); Rf 0.05 (100% EtOAc,
KMnO4 stain); mp 45−52 °C; IR νmax (film)/cm−1 3426, 2974, 2933,
2868, 2812, 1695; 1H NMR (300 MHz, CDCl3) δ: 3.61 (t, J = 5.4 Hz,
2H), 3.42 (t, J = 5.1Hz, 4H), 2.54 (t, J = 5.4 Hz, 2H), 2.44 (t, J = 5.1Hz,
4H), 1.45 (s, 9H) (alcohol OH signal not seen); 13C NMR (75 MHz,
CDCl3) δ: 154.8, 79.8, 59.5, 57.9, 52.9, 28.6 (1 obscured signal).
Spectroscopic data matched those in the literature.59
3-Cubylpropan-1-ol (S3). Adapted from the procedure of Priefer et
al.:60 3-Cubylacetic acid (58.0 mg, 0.36 mmol) was suspended in
anhydrous THF (5mL) under Ar. Borane dimethylsulfide complex (2.0
M in Et2O, 0.51 mL, 1.02 mmol) was added, and the solution was
stirred for 16 h. Sat. aq. NH4Cl (1 mL) was cautiously added, and the
mixture was stirred for 20 min. The THF was removed in vacuo, and the
residue was then diluted with H2O (10 mL) and extracted with CH2Cl2
(3 × 10 mL). The combined organic layers were dried (MgSO4),
filtered, and concentrated under reduced pressure. The crude product
was purified by flash chromatography on silica (50% EtOAc in
petroleum ether) to give S3 as a yellow oil (55.0 mg, 94%); IR νmax
(film)/cm−1 3307, 2968, 1444, 1214, 1054, 881, 841; 1H NMR (400
MHz, CDCl3) δ: 4.07−4.01 (m, 1H), 3.87−3.84 (m, 3H), 3.74−3.71
(m, 3H), 3.65 (t, J = 6.6 Hz, 2H), 1.65−1.54 (m, 4H), 1.36 (br s, 1H);
13C NMR (101 MHz, CDCl3) δ: 63.5, 59.0, 48.7, 48.5, 44.2, 29.4, 27.7;





lowing the procedure of Aleksandrov et al.:61 Octahydro-1H-2,4,1-
(epiethane[1,1,2]triyl)cyclobuta[cd]pentalen-7-one (150 mg, 0.94
mmol, 1.0 equiv) was dissolved in pyridine (1 mL), and isopropylidene
malonate (162 mg, 1.12 mmol, 1.2 equiv) was added. The mixture was
agitated several times within the first hour to dissolve the acid and then
left to stand for 5 days. The reaction mixture was poured over H2O (20
mL), and the precipitate was filtered to give the crude product as a white
powder (153 mg, 57%); carried forward without further purification;
the remaining crude material was purified by recrystallization from 50%
aq. acetone to give S4 as white plates; mp 160−164 °C (lit.61 157−158
°C); IR νmax (film)/cm−1 1726, 1606; 1H NMR (400 MHz, CDCl3) δ:
4.24 (ddd, J = 8.4, 5.9 & 2.4 Hz, 1H), 4.16−3.98 (m, 1H), 3.18 (td, J =
8.6 & 3.5 Hz, 1H), 2.94 (d, J = 10.1 Hz, 1H), 2.79 (q, J = 6.4 & 6.0 Hz,
1H), 2.66 (q, J = 7.0 & 6.4 Hz, 1H), 2.58−2.45 (m, 2H), 1.92 (d, J =
10.9 Hz, 1H), 1.71 (d, J = 5.3 Hz, 6H), 1.52 (d, J = 10.9 Hz, 1H), 1.40−
1.15 (m, 2H); 13C NMR (101 MHz, CDCl3) δ: 194.6, 161.2, 161.0,
111.5, 103.9, 50.8, 50.6, 47.8, 47.5, 44.2, 43.0, 42.8, 39.8, 36.9, 30.9,
27.7, 27.1. Spectroscopic data matched those in the literature.61
2,2-Dimethyl-5-(octahydro-1H-2,4,1-(epiethane[1,1,2]triyl)-
cyclobuta[cd]pentalen-7yl)-1,3-dioxane-4,6-dione (S5). Following
the procedure of Aleksandrov et al.:61 Compound S4 (120 mg, 0.42
mmol, 1.0 equiv) was suspended in EtOH (8 mL), and NaBH4 (17.4
mg, 0.42 mmol, 1.1 equiv) was added portionwise keeping the
temperature below 30 °C. The reaction was stirred for 1 h and then
filtered. The filtrate was reduced to half the volume and poured onto a
H2O (8 mL) and AcOH (0.13 mL) mixture and left to stand for 2 h.
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The solid was filtered, washed with H2O, and dried in vacuo to give the
crude product as white crystals (91.8mg, 76%); carried forward without
further purification; the remaining crude material was purified by
recrystallization from 50% aq. acetone to give S5 as white plates; mp
138−143 °C (lit.61 136−137 °C); IR νmax (film)/cm−1 1742; 1H NMR
(400 MHz, CDCl3) δ: 3.91 (d, J = 9.9 Hz, 1H), 3.05−2.73 (m, 2H),
2.59 (qd, J = 12.2, 10.8 & 4.8 Hz, 3H), 2.47 (d, J = 8.8 Hz, 1H), 2.24 (br
d, J = 17.9 Hz, 2H), 1.92 (dt, J = 9.9 & 3.1 Hz, 1H), 1.81 (d, J = 13.2 Hz,
1H), 1.73 (d, J = 8.1 Hz, 6H), 1.70 (sapp, 1H), 1.30−1.08 (m, 2H); 13C
NMR (101 MHz, CDCl3) δ: 166.0, 165.8, 105.4, 47.4, 46.4, 46.3, 44.3,
42.5, 42.1, 41.7, 41.5, 38.4, 36.4, 34.1, 29.2, 28.8, 28.3. Spectroscopic
data matched those in the literature.61
2-(Octahydro-1H-2,4,1-(epiethane[1,1,2]triyl)cyclobuta[cd]-
pentalen-7-yl)acetic acid (S6). Following the procedure of Aleksan-
drov et al.:61 Compound S5 (65.0 mg, 0.23 mmol) was dissolved in a
mixture of AcOH (0.5 mL) and conc. HCl (0.1 mL) and heated at
reflux for 2.5 h. The reaction was cooled to rt and poured onto H2O
(3.75 mL), cooled in ice, filtered, and washed with H2O to give the
crude product as an off-white powder (32.5 mg, 70%); carried forward
without further purification; the remaining crude material was purified
by recrystallization from hexane to give S6 as white crystals; 1H NMR
(300 MHz, CDCl3) δ: 2.82−2.49 (m, 6H), 2.30 (br s, 1H), 2.27−2.14
(m, 4H), 1.93 (tt, J = 6.8 & 2.8 Hz, 1H), 1.69 (s, 1H), 1.68−1.59 (m,
1H), 1.17 (d, J = 10.7 Hz, 1H), 1.03 (dt, J = 12.7 & 3.5 Hz, 1H).
Spectroscopic data matched those in the literature.61
2-(Octahydro-1H-2,4,1-(epiethane[1,1,2]triyl)cyclobuta[cd]-
pentalen-7-yl)ethan-1ol (S7). Compound S6 (25.0 mg, 0.12 mmol, 1
equiv) was dissolved in anhydrous THF (1 mL) and cooled to 0 °C.
LiAlH4 (1 M in THF, 78.3 μL, 78.3 μmol, 0.64 equiv) was added
dropwise, and the reaction was mixture was stirred for 10 min at 0 °C
and then at rt. The reaction was cooled in an ice bath, and the LAHwas
quenched with EtOAc dropwise. A sat. aq. solution of Rochelle’s salt
was added, and the mixture was stirred at 0 °C and then at rt for 1.5 h.
The organic layer was separated, and the aqueous layer was extracted
with EtOAc (2×). The combined organic layers were dried (MgSO4),
filtered, and concentrated under reduced pressure to give the crude
product as a clear oil (25.6 mg, >100%); carried forward without further
purification or characterization.
(3-(Difluoromethyl)bicyclo[1.1.1]pentan-1-yl)methanol (S8). 3-
(Difluoromethyl)bicyclo[1.1.1]pentane-1-carboxylic acid (25.8 mg,
159 μmol, 1.0 equiv) was dissolved in THF (72.3 μL, 2.2 M) and
cooled to 0 °C. LiAlH4 (1 M in THF, 239 μL, 239 μmol, 1.5 equiv) was
added, and the reaction was allowed to warm to rt. The reaction was
quenched with H2O (18 μL) and anhydrous Na2SO4 (103 mg) and
stirred for 20 min. The mixture was filtered, washed with THF, and the
filtrate was concentrated under reduced pressure to give S8 as a pale
yellow oil (19.6 mg, 83%); carried forward without further purification
or characterization; Rf 0.34 (25% EtOAc in hexanes, KMnO4 stain);
1H
NMR (200 MHz, CDCl3) δ: 5.70 (t, J = 56.5 Hz, 1H), 3.66 (s, 2H),
1.81 (s, 6H) (alcohol OH signal not seen).
1,2-Dicarba-closo-dodecaborane-1-ethanol (S9). Following the
procedure of Li et al.:62 To a solution of closo-1,2-carborane (100 mg,
0.69 mmol, 1 equiv) in anhydrous THF (2.25 mL) was added n-BuLi
(1.6 M in hexanes, 0.43 mL, 0.69 mmol, 1 equiv) at −78 °C under N2.
Stirring was continued for 30 min, then ethylene oxide (2.5 M in THF,
0.42 mL, 1.04 mmol, 1.5 equiv) was added dropwise. Stirring was
continued for 1 h at 0 °C, then the reaction was quenched with sat. aq.
NH4Cl (1 mL). The aqueous phase was extracted with EtOAc (3 × 1.5
mL), and the combined organic layers were dried (Na2SO4), filtered,
and concentrated under reduced pressure to give the crude product,
which was purified by automated flash chromatography on silica
(Biotage Isolera, 5−40% EtOAc in hexanes) to give S9 as a white solid
(110 mg, 66%); 1H NMR (400 MHz, CDCl3) δ: 3.98 (br s, 1H), 3.79
(t, J = 5.9 Hz, 2H), 2.49 (t, J = 5.9 Hz, 2H), 2.80−1.42 (m, 11H); 13C
NMR (101 MHz, CDCl3) δ: 73.2, 60.8, 60.7, 39.9; m/z (ESI−) 189
([M − H]−, 100%); HRMS (ESI−) found 189.2058 ([M − H]−),
C4H15B10O
− requires 189.2059. Spectroscopic data matched those in
the literature.63
1,7-Dicarba-closo-dodecaborane-1-ethanol (S10). Adapted from
the procedure of Li et al.:62 To a solution of closo-1,7-carborane (100
mg, 0.69 mmol, 1 equiv) in anhydrous THF (2.25 mL) was added n-
BuLi (1.6 M in hexanes, 0.43 mL, 0.69 mmol, 1 equiv) at−78 °C under
N2. Stirring was continued for 30 min, then ethylene oxide (2.5 M in
THF, 0.42 mL, 1.04 mmol, 1.5 equiv) was added dropwise. Stirring was
continued for 1 h at 0 °C, then the reaction was quenched with sat. aq.
NH4Cl (1 mL). The aqueous phase was extracted with EtOAc (3 × 1.5
mL), and the combined organic layers were dried (Na2SO4), filtered,
and concentrated under reduced pressure to give the crude product,
which was purified by automated flash chromatography on silica
(Biotage Isolera, 6−50% EtOAc in hexanes) to give S10 as a white solid
(30.7 mg, 23%); Rf 0.47 (25% EtOAc in hexanes, KMnO4 stain);
1H
NMR (200 MHz, CDCl3) δ: 3.88−3.32 (m, 2H), 2.94 (s, 1H), 2.51−
2.00 (m, 2H), 3.29−0.71 (m, 11H); m/z (APCI+) 191 ([M + H]+,
100%); HRMS (ESI−) found 189.2058 ([M − H]−), C4H15B10O−
requires 189.2059. Spectroscopic datamatched those in the literature.64
1-(2-Benzyloxyethyl)-1,12-dicarba-closo-dodecaborane (S11).
Following the procedure of Fujii et al.:65 To a solution of closo-1,12-
carborane (120 mg, 0.83 mmol, 1.0 equiv) in anhydrous Et2O (2.88
mL) was added n-BuLi (1.6 M in hexanes, 572 μL, 0.92 mmol, 1.1
equiv) at 0 °C under Ar. The mixture was stirred at rt for 1 h, then
benzyl 2-bromoethyl ether (163 μL, 1.00 mmol, 1.2 equiv) was added,
and the reaction was stirred for 16 h. The reaction was cooled to 0 °C,
quenched with H2O, and diluted with EtOAc. The organic layer was
washed withH2O and brine, dried (Na2SO4), filtered, and concentrated
under reduced pressure to give the crude product, which was purified by
automated flash chromatography on silica (Biotage Isolera, 6−50%
EtOAc in hexanes) to give S11 as a clear colorless oil (108 mg, 47%); Rf
0.83 (10% EtOAc in hexanes, KMnO4 stain);
1H NMR (200 MHz,
CDCl3) δ: 7.63−6.97 (m, 5H), 4.40 (s, 2H), 3.26 (t, J = 7.2 Hz, 2H),
2.64 (br s, 1H), 1.95 (t, J = 7.1 Hz, 2H), 3.72−0.63 (m, 10H).
Spectroscopic data matched those in the literature.65
1,12-Dicarba-closo-dodecaborane-1-ethanol (S12). Adapted
from the procedure of Mandal et al.:66 Compound S11 (90 mg, 0.32
mmol, 1.00 equiv) and 5%Pd/C (34.4mg, 0.02mmol, 0.05 equiv) were
suspended in EtOH (2 mL). The mixture was purged with Ar, Et3SiH
(0.52mL, 3.23mmol, 10.0 equiv) was added dropwise, and the reaction
was stirred at rt. The mixture was filtered through a pad of celite and
concentrated under reduced pressure to give S12 as a pale yellow solid
(40.7 mg, 67%); carried forward without further purification; Rf 0.26
(10% EtOAc in hexanes, KMnO4 stain);
1H NMR (400 MHz, CDCl3)
δ: 3.45 (t, J = 7.0 Hz, 2H), 2.66 (br s, 1H), 2.91−1.26 (m, 11H), 1.90 (t,
J = 7.0 Hz, 2H). Spectroscopic data matched those in the literature.63
4-Iodobenzaldehyde (S13). Following the procedure of Yamashita
et al.:67 1,3-Dimethyl-2-imidazolidinone (15 mL) was added to 4-
bromobenzaldehyde (1.00 g, 5.40 mmol, 1.0 equiv), KI (8.07 g, 48.6
mmol 9.0 equiv), and CuI (3.19 g, 17.8 mmol, 3.1 equiv). The mixture
was purged with N2 and heated under vigorous stirring at 200 °C for 23
h. After cooling to rt, brine and ice were added, and the reaction was
placed in an ice bath for 3 h. The precipitated inorganic salts were
removed by filtration, and the filtrate was extracted with Et2O. The
combined organic layers were washed with brine, dried (Na2SO4),
filtered, and concentrated under reduced pressure to give the crude
product, which was purified by automated flash chromatography on
silica (Biotage Isolera, 12−75% EtOAc in hexanes) to give S13 as a
yellow powder (263 mg, 21%); Rf 0.87 (50% EtOAc in hexanes); mp
72−79 °C (lit.68 77−78 °C); 1H NMR (400 MHz, CDCl3) δ: 9.96 (s,
1H), 7.91 (d, J = 8.2 Hz, 2H), 7.59 (d, J = 8.5 Hz, 2H); 13C NMR (101
MHz, CDCl3) δ: 191.5, 138.6, 135.7, 130.9, 103.0. Spectroscopic data
matched those in the literature.67
1-Iodo-4-(hydroxymethyl)cubane (S14). Following the procedure
of Griffiths et al.:69 4-Iodocubanecarboxylic acid65 (200 mg, 0.73
mmol) was dissolved in anhydrous THF (7mL) under Ar and cooled to
0 °C. Borane dimethylsulfide complex (0.23 mL, 1.16 mmol) was
added, and the reaction was stirred at 0 °C for 20min and then at rt for 4
h. The solution was quenched with H2O and stirred overnight. After
adding EtOAc, the solution was washed with H2O and brine, dried
(MgSO4), filtered, and concentrated under reduced pressure to give
S14 as a white solid (162 mg, 85%); carried forward without further
purification; Rf 0.80 (100% EtOAc);
1H NMR (300 MHz, CDCl3) δ:
4.21 (dd, J = 5.8 & 4.4 Hz, 3H), 4.04 (dd, J = 5.8 & 4.2 Hz, 3H), 3.77 (s,
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2H) (alcohol OH signal not seen); 13C NMR (75 MHz, CDCl3) δ:
63.2, 59.1, 54.8, 48.0, 39.0. Spectroscopic data matched those in the
literature.69
1-Iodocubane-4-carboxaldehyde (S15). Following the procedure
of Griffiths et al.:69 A stirring solution of oxalyl chloride (63.8 μL, 0.75
mmol) in anhydrous CH2Cl2 (1 mL) was prepared under Ar at−78 °C.
Anhydrous DMSO (0.11 mL, 1.54 mmol) in anhydrous CH2Cl2 (1
mL) was added dropwise. After 20 min at −78 °C, a solution of S14
(162 mg, 0.62 mmol) in anhydrous CH2Cl2 (4.25 mL) was added
dropwise under Ar. The mixture was maintained at −78 °C for 1.5 h,
then anhydrous Et3N (0.39 mL, 2.80 mmol) was added. The mixture
was warmed to rt and quenched with H2O (4 mL). The aqueous layer
was extracted with CH2Cl2 (2 × 4 mL), and the combined organic
layers were washed with H2O (4 mL) and brine (4 mL), dried
(MgSO4), filtered, and concentrated under reduced pressure to give the
crude product, which was purified by automated flash chromatography
on silica (Biotage Isolera, 12−100% EtOAc in hexanes) to give S15 as a
white solid (130 mg, 81%); Rf 0.84 (50% EtOAc in hexanes); mp 124−
130 °C (lit.69 106−109 °C); 1H NMR (300 MHz, CDCl3) δ: 9.74 (s,
1H), 4.56−4.47 (m, 3H), 4.33−4.25 (m, 3H); 13C NMR (75 MHz,
CDCl3) δ: 197.1, 62.8, 54.8, 49.0, 35.6. Spectroscopic data matched
those in the literature.69
In Vitro Antiplasmodial Activity (Drug Discovery Unit,
University of Dundee).70 Cultures of the widely used malaria
reference strain of chloroquine-sensitive P. falciparum strain 3D7 were
maintained in a 1.25 or 5% suspension of human red blood cells
cultured in RPMI 1640 medium supplemented with 0.5% Albumax II
(available from Gibco Life Technologies, San Diego, CA; cat. no.
11021-037), 12 mM sodium bicarbonate, 0.2 mM hypoxanthine, (pH
7.3), and 20mg/L gentamicin at 37 °C, in a humified atmosphere of 1%
O2 and 3%CO2, with a gas balance of nitrogen. Growth inhibition of the
P. falciparum cultures was quantified in a 10-point dose−response curve
with a 1 in 3 dilution series. This 384-well plate-based fluorescence
assay utilizes the binding of SYBRgreen I (Thermo Fisher Scientific/
Invitrogen; cat. no. S7585) to double-stranded DNA, which greatly
increases the fluorescent signal at 528 nm after excitation at 485 nm.
Mefloquine was used as a drug control to monitor the quality of the
assay (Z′ = 0.6 to 0.8, where Z′ is a measure of the discrimination
between the positive and negative controls on a screen plate). Dose−
response curves were determined from a minimum of three
independent experiments. Compound bioactivity was expressed as
IC50, the concentration of compound causing 50% inhibition. IC50
values were determined from a minimum of three independent
experiments. All data were processed using IDBS ActivityBase, and raw
data were converted into percent inhibition through linear regression
by setting the high inhibition control as 100% and the no inhibition
control as 0%. Quality control criteria for passing plates were as follows:
Z′ > 0.5, S:B > 3, %CV (no inhibition control) < 15. The formula used
to calculate is ′ = −
× +
−Z 1




. All IC50 curve fitting was






C x1 ( / )D
where A = % inhibition at bottom, B =% inhibition at top, C = IC50,D =
slope, x = inhibitor concentration, and y = % inhibition. If the curve did
not reach 100% of inhibition, B was fixed to 100 only when at least 50%
of inhibition was reached.
Cytotoxicity Studies (Drug Discovery Unit, University of
Dundee).70 In vitro cytotoxicity studies were carried out using HepG2
(Human Caucasian hepatocyte carcinoma, ECACC; cat. no.
85011430) as indicators for general mammalian cell toxicity. HepG2
in vitro cytotoxicity can be assessed using the assay procedure, as
described.71
Kinetic Solubility Estimation using Nephelometry (Centre
for Drug Candidate Optimization, Monash Institute of
Pharmaceutical Sciences). Compound in DMSO was spiked into
either pH 6.5 phosphate buffer or 0.01 M HCl (pH ∼ 2.0) at seven
concentrations with the final DMSO concentration of each being 1%.
After 30 min, the samples were then analyzed for precipitation via
nephelometry to determine the solubility range.72
Distribution coefficient was estimated using chromatography
(Centre for Drug Candidate Optimization, Monash Institute of
Pharmaceutical Sciences). Partition coefficient values (LogD) of the
test compounds were estimated at pH 7.4 by correlation of their
chromatographic retention properties (mean of two injections) against
the characteristics of a series of standard compounds with known
partition coefficient values. The method employed is a gradient HPLC-
based derivation of the method developed by Lombardo.73
In Vitro Metabolic Stability (Centre for Drug Candidate
Optimization, Monash Institute of Pharmaceutical Sciences).
The metabolic stability assay was performed by incubating each test
compound with liver microsomes at 37 °C and a protein concentration
of 0.4 mg/mL. The metabolic reaction was initiated by the addition of
an NADPH-regenerating system and quenched at five time points over
a 60 min incubation period by the addition of acetonitrile containing
diazepam as the internal standard. Control samples (containing no
NADPH) were included (and quenched at 2, 30, and 60 min) to
monitor potential degradation in the absence of cofactor. All liver
microsomes used in these experiments were purchased fromXenoTech.
Microsomal incubations were performed at a substrate concentration of
1 μM. The half-life and intrinsic clearance were determined by
exponential regression of the concentration vs time data.
Late-Stage Biofunctionalization of Compounds 16 and 19
(Obach Lab, Pfizer).Compound 19 (40 μM) was incubated with dog
liver microsomes (1 mg/mL) in a total volume of 40 mL of potassium
phosphate buffer (0.1 M; pH 7.4) containing MgCl2 (3.3 mM) and
NADPH (1.3 mM). The incubation was done in a 500 mL Erlenmeyer
flask in a shaking water bath maintained at 37 °C open to the air. After 1
h, the incubation was terminated by addition of MeCN (40 mL) and
the precipitated protein was removed by spinning at 1700g for 5 min.
The supernatant was partially evaporated in a vacuum centrifuge for 1.5
h, and to the remaining liquid was added formic acid (0.5 mL), MeCN
(0.5 mL) andH2O to a final volume of 50 mL. This mixture was spun in
a centrifuge at 40 000g for 30min. The clarified supernatant was applied
to a Varian Polaris C18 column (4.6 mm × 250 mm; 5 μm) at 0.8 mL/
min through a Jasco HPLC pump. After the entire solution was applied
and another 5 mL of 0.1% formic acid in H2O was washed through the
system, the column was moved to an HPLC-UV-MS (Thermo Velos
LTQ mass spectrometer, equipped with a Waters Acquity HPLC-UV
system) in line with a fraction collector (Leap Analytics). A mobile
phase gradient was applied at 0.8 mL/min beginning with 2%MeCN in
0.1% aqueous formic acid, raised to 20% MeCN at 1 min, held until 5
min, then increased linearly to 55% MeCN at 80 min, followed by a 10
min wash at 95% MeCN and 10 min reequilibration to initial
conditions. Fractions were collected every 20 s. Fractions predicted to
contain products of interest eluted around 39.5 and 42.0 min and were
individually analyzed on a Thermo Orbitrap Elite UHPLC-UV-HRMS
system to ascertain identity and purity for pooling and qNMR analysis.
Pooled fractions were evaporated in a vacuum centrifuge, and the
residue was taken up in DMSO-d6 (0.05 mL). Compound 16 was
subjected to a similar procedure except that rabbit liver microsomes
were used as the source of enzyme, the substrate concentration was 25
μM, and the incubation time was 45 min. The fractionation was carried
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